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Population studies have shown that HIV-infected individuals co-infected with Mycobacterium 
tuberculosis (MTB) are at up to 10-fold higher risk of developing active tuberculosis (TB) than 
their seronegative counterparts. Co-infected individuals also progress faster to AIDS than 
patients infected only with the virus. Therefore, understanding the relation between these 
two diseases is of a crucial importance. The overall aim of this thesis was to investigate the 
interaction between HIV and MTB infection from the perspective of host immunity. Using in 
vitro and in vivo models, we investigated innate and adaptive immune responses to better 
understand the mechanisms behind the increased susceptibility to MTB and HIV during co-
infection. 
In the first study we examined regulation of the host immune response during pulmonary TB 
mediated by CD103+ dendritic cells (αE-DC) and CD4+ Foxp3+ regulatory T (Treg) cells. We 
found that in resistant mice, the number of lung αE-DCs increased dramatically during MTB 
infection. In contrast, susceptible DBA/2 mice which failed to recruit αE-DCs even during 
chronic infection. αE-DCs remained essentially TNF negative but contained a high number of 
TGFβ-producing cells in the lungs of infected mice. Further, we show that Treg cells in resistant 
and susceptible mice induced interferon IFNγ during pulmonary TB. We also showed that the 
Treg cell population was diminished in the lungs, but not in the draining pulmonary lymph 
nodes, of susceptible mice. The reduced number of lung Treg cells in susceptible mice 
coincided with an increased bacterial load and exacerbated lung pathology compared to 
resistant strains. These results demonstrate that immune-regulatory mechanisms may play an 
important role in protective immune responses during pulmonary TB. 
In study II we analyzed the impact of MTB-infected macrophages on DC functionality, 
including HIV transinfecting ability. An in vitro system was used in which human monocyte-
derived DCs were exposed to soluble factors released by MTB- or BCG-infected macrophages. 
Soluble factors secreted from infected macrophages resulted in the production of 
proinflammatory cytokines and partial upregulation of maturation markers on DCs. 
Interestingly, the HIV transinfecting ability of DCs was enhanced In summary, this study shows 
that DCs respond to soluble factors released by mycobacteria-infected macrophages. These 
findings highlight the important role of bystander effects mediated by MTB-infected 
macrophages, and suggest it contributes to DC-mediated HIV spread and amplification in co-
infected individuals. 
In study III we assessed the impact of MTB infection on the immunogenicity of a HIV vaccine. 
We found that, depending on the vaccination route, mice infected with MTB before the 
administration of the HIV vaccine showed impairment in both the magnitude and the quality 
of antibody and T cell responses directed towards the vaccine. Mice infected with MTB prior 
to HIV vaccination exhibited reduced IgG and IgA antibody levels and neutralizing activity of 
serum against the virus In addition mice infected with MTB had significantly lower HIV-specific 
multifunctional T cells. These results suggest that chronic MTB infection might interfere with 
the outcome of prospective HIV vaccination in humans. 
In study IV we developed a new murine model of MTB/HIV co-infection using conventional, 
immunocompetent mouse strains. We utilized the chimeric EcoNDK virus together with a low 
dose MTB aerosol infection. To date, we have observed that the viral burden increased in the 
spleen and in the lungs of animals infected with MTB prior to virus inoculation. We have also 
shown that co-infection did not affect control of bacterial growth. During the early stage of co-
infection, EcoNDK induced a significantly higher frequency of MTB antigen-specific CD8+ T-
cells in the spleen. Also, MTB-specific CD8+ T-cells in both MTB-infected and MTB/EcoNDK co-
infected animals were enriched for Tim3- and PD1 expressing cells.  
In conclusion, this small animal model may provide a useful tool to increase our understanding 
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1.1 EPIDEMIOLOGY OF MYCOBACTERIUM TUBERCULOSIS (MTB), HUMAN 
IMMUNODEFICIENCY VIRUS (HIV) AND MTB/HIV CO-INFECTION 
The earliest evidence that humans developed tuberculosis came from ancient 
Egyptian mummified remains from 3,400 BC. Recent genetic studies of the whole MTB 
genome advocate that a common mycobacterial progenitor could have infected our 
early hominid ancestors as long as 3 million years ago [1], [2]. The first scientific 
characterization of the agent causing TB was identified by Robert Koch in 1882 and 
was named Mycobacterium tuberculosis (MTB )due to its ability to cause tubercle 
formations in the lungs. In spite of the discovery of antibiotics, global vaccination 
programs and populational diagnostic screening, it is estimated that today 2 billion 
people worldwide are MTB-infected. As a result, TB accounts for 2-3 million deaths 
annually [3].  
The incident rate has dropped greatly in developed countries since Robert Koch’s 
time, when 1 in 7 deaths was attributed to TB that was then incurable. Today, it is 
estimated that the TB incidence rate is 139/100,000 worldwide, which corresponds to 
less than 10 million active TB cases globally. Although there is a significant global 
decline when compared to the predictions from the 1990’s, the data represent an 11% 
increase in the incident rate and a staggering 40% increase in the number of new 
active TB cases [4]. The majority of newly infected individuals were diagnosed in Sub-
Saharan Africa and Asia, as well as certain communities in Europe. The TB incidence 
and TB-associated deaths in Sub-Saharan Africa has more than doubled in the 90’s. 
The estimated TB-related deaths has tripled compared to the WHO predictions [4]. It 
was soon realized that new the strength of the TB epidemic was associated with the 
new emerging HIV pandemic. Although the incident rate has been declining thanks to 
the introduction of new health programs like Directly Observed Treatment, Short-
course (DOTS), or preventive antiviral therapy for acquired immunodeficiency 
syndrome (AIDS), the overall number of new TB cases is still increasing due to global 
population growth. This is reflected by the fact that over 50% of all new TB cases are 
reported in Asia. Over 20% of all screened TB patients has been identified as HIV 
seropositive [3], [4]. 
In contrast to TB, HIV was discovered less than 30 years ago and described as the 
causative agent of AIDS [5], [6]. Today, over 30 million people are estimated to be 
infected with HIV, with 2.7 million new infections and over 2 million deaths caused by 
AIDS every year. The fact that over 2.1 million children are infected with the virus is 
most tragic. As in the case of TB, areas of the highest disease prevalence are located in 
Sub-Saharan Africa where more than 60% of all infected individuals live [7], [8]. 
Determining the accurate epidemiological picture of the HIV epidemic is problematic 
since the majority of individuals infected with HIV are not aware of that fact. In highly 
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endemic countries, new programs of population screening are being installed. Still, 
providing robust diagnostic tests is a monumental task due to the logistics of the 
operation in remote areas. Nevertheless, over 4 million individuals were treated with 
antiretroviral therapy (ART) or high active antiretroviral therapy (HAART) in 2008 
comparing to less than 3 in 2007 [7]. Initially, it was hoped that the antiretroviral 
treatment would be able to eradicate the virus from the patients and subsequently 
the pandemic would be controlled within 20 years. Now, it is estimated that 
eradication of all infected cells from the patients’ body would require 60-70 years of 
treatment. In spite of that, it is promising that with the new generation of drugs, HIV 
infection is being treated as a chronic disease, and as such kept under control by 
lifelong therapy [9].  
Figure 1.  Overlay of the global indidences of HIV and TB in 2009. Based on WHO and 
UNAIDS maps [3], [7]  
1.2 HIV 
1.2.1 HIV history and diversity  
The probable origins of HIV infection in humans can be found in multiple zoonotic 
transmissions of simian immunodeficiency virus (SIV) between nonhuman primates 
and humans in Central-West Africa. More than 30 different species of nonhuman 
primates are natural hosts of species-specific SIV, Thus, independent, multiple, 
cross-species infections resulted in different lineages of the virus [10]. There are two 
main types of HIV: HIV type 1 (referred to as “HIV”) being the main cause of the 
global epidemic and HIV type 2 (HIV-2) that infects only a limited number of 
individuals, mainly in Central West Africa. HIV-2 is around 40% genetically different 
from HIV type 1. Within those two types several lineages have been identified: HIV 
type 1 consists of groups M, N, O and P with a genetic variation close to 30% 
H
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between the groups, and HIV-2 groups A–H with half the variation [11]. In the case 
of HIV type 1, the group M (M for main) is responsible for the global HIV pandemic. 
Group O has been estimated to be present in not more than 100 000 individuals and 
groups N and P have only been identified in a few of individuals in Cameroon [12]. 
Although HIV was identified in 1983, it is speculated that transmission to humans 
happened already approximately around 1900. Since the two oldest isolates from 
1959 and 1960 already differed genetically by ~12% (belonging to two different 
subtypes: A and D) we now know that fast genetic diversification of group M was 
already taking place before the explosion of the epidemic [13]. During the course of 
the HIV pandemic this process accelerated, leading to massive genetic diversity. 
Within the main group M, nine subtypes were identified: A–D, F–H, J and K with 
genetic variation levels of 8-17% within the subtypes and reaching up to 42% 
between them [14]. This astonishing diversity is characteristic for retroviruses and is 
attributed to their unique replication cycle. The HIV genome consists of two copies 
of 10kb single-stranded ribonucleic acid (RNA) [9]. As in all retroviruses, the genomic 
RNA of the virus needs to be transcribed by the viral reverse transcriptase (RT) to 
deoxyribonucleic acid (DNA), which can then be incorporated into the genome of 
the host cell. Due to the lack of proofreading activity of the RT, the mutation rate of 
the virus is extremely high (3,4 x 10
-5 
m/bp for each replication cycle) [15]. This 
process alone is responsible for generating millions of virus variants in a single 
infected individual. Additionally, the RT is also responsible for a recombination 
process occurring between the two strands of RNA leading to additional variation in 
viral genetic pool and rapid virus evolution [16]. 
1.2.2 HIV structure and lifecycle 
1.2.2.1 Envelope proteins and impact on co-receptor recognition 
The genome of HIV is composed of 9 genes, encoding at least 15 viral proteins,  
which can be divided further into three main groups. Three structural genes: env, 
gag and pol, two regulatory genes: tat and rev, and a group of four accessory genes: 
nef, vif, vpu and vpr. Non-coding long terminal repeat sequences (LTRs) located at 
both ends of the genome are required for viral genome integration, and are 
together with the viral and cellular proteins involved in controlling the production of 
new viruses [9]. The genetic material of the virus is carried as two positive strands of 
ssRNA which are encapsulated in the nucleocapsid made of p24 protein and 
additional enzymes and accessory proteins needed in the first steps of infection, 
most importantly the RT. The capsid itself is enclosed by the remains of the cellular 
lipid plasma membrane and the HIV matrix-protein in which the glycoproteins gp120 
and gp41 are anchored. Those two products of the env gene are derived from the 
gp160 precursor which is being processed by host cell proteases into gp120, which 
are the main surface protein interacting with the CD4 receptor of the target cells, 
and the gp41 protein being the main anchor of the complex in the envelope. The 
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gp120 protein binding the host cell receptor is responsible for the host-cell 
specificity of HIV. Therefore, differences in the gp120 protein among the viruses 
impact their tropism [17]. The CD4 molecule, that is expressed on the surface of T-
cells and macrophages, is the main receptor for HIV, although the virus can also bind 
to the C-type lectin receptor, such as DC-SIGN, on the surface of dendritic cells [18]. 
Binding only to the CD4 molecule is not sufficient for viral entry. Prior to entry into 
the cell, the gp120 protein needs to go through conformational changes triggered by 
binding to the CD4 molecule, and binding to one of various co-receptors, mainly 
CXCR4 and CCR5 [19]. Subsequently, gp41 also changes its conformation and thus 
allows for membrane fusion and entry of the virus into the host cell. Huge genetic 
variation of the virus leads to alterations in the molecular structure of gp120. This 
leads to recognition of different co-receptors, whereas the CD4 molecule remains 
the main receptor. R5 viruses, which recognize CCR5 as the co-receptor, are 
predominantly present in the early stages of infection. In about half of the cases, 
during the course of the disease, one can observe a shift in the co-receptor variants 
of the virus. In late stages of the disease, the CXCR4-recognizing viruses (X4 viruses), 
or viruses being able to recognize both co-receptors (R5X4 viruses), become the 
dominating variants [20] The CCR5 co-receptor is expressed only on a small fraction 
of memory CD4+ T-cells, while the expression of CXCR4 is high on naïve T-cells. In 
the early stages of the infection it is the CCR5 expressing cells which are the main 
target for the virus. Dominance of the CCR5 strain at this stage is probably 
associated with the high frequency of the memory CD4+ T-cells in the gut-associated 
lymphoid tissue (GALT), where robust virus replication takes place soon after 
infection. In less than a few months, up to 80% of all CD4+ T-cells in the GALT are 
destroyed, even though only ~20% of the cells are actually HIV-infected [21]. The 
importance of co-receptor recognition can be best observed in the case of 
individuals who are homozygous carriers of CCR5 delta 32 receptor mutations. This 
mutation prevents binding of the virus to the co-receptor making carries immune to 
R5 virus infection [22]. 
HIV is able to infect not only CD4+ T-cells, but also macrophages and DCs. Recent 
findings suggest that macrophage susceptibility to HIV infection relies on the 
expression of different chemokine receptors. Both CCR5 and CXCR4 can be 
expressed by monocyte-derived macrophages but the level of expression is strictly 
tissue dependent [23]. Intestinal macrophages express very low levels of the CCR5 
chemokine receptor in contrast to the macrophages in vaginal mucosa, which have 
been shown to be highly susceptible to R5 virus infection [24][25]. In the brain 
tissue, macrophages and microglia mainly express more CXCR4 than CCR5. Thus, in 
late stages of the infection, neurodegenerative symptoms could be partially 
associated with the emergence of X4 and R5X4 variants [26]. Similarly, DCs can 
express both types of co-receptors but their susceptibility to certain variants is 
skewed towards R5 type viruses [27]. DCs also contribute indirectly to differential 
propagation of R5 virus strains. By producing CCR5 ligands, vaginal mucosa DCs 
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attract CD4+ T-cells expressing CCR5 to the site of infection and therefore enrich the 
pool of T-cell being infected by the R5 viruses [28]. Besides their HIV replication in-
cis, DCs contribute to viral dissemination into CD4+ T cells via a DC-SIGN trans-
infection mechanism [28]. As mentioned before, gp120 can bind not only to the CD4 
receptor, but also to a C-type lectin receptor such as DC-SIGN, which is present 
mainly on the surface of DCs. It normally functions as a receptor in the adhesion 
process and plays a role in an internalization of the captured antigens. DC-SIGN is 
able to bind and facilitate internalization of various pathogens like Hepatitis C, 
Dengue, Ebola, MTB or Helicobacter pylori and therefore start the process of 
phagocytic degradation followed by antigen presentation [22]. Surprisingly, HIV 
escapes this degradation process and stays intact for the duration of the migration 
of the DC from the site of infection to secondary lymphoid organs, and thereby 
facilitates virus transmission to areas rich in main virus targets: CD4+ T-cells [29]. 
1.2.2.2 Inside the host(ile) cell  
Successful virus infection hinges on the ability of the virus to turn the host cell into a 
submissive state in which the main objective is to turn cellular metabolism into 
production of new virus particles. To achieve that, viruses depend on a spectrum of 
accessory and regulatory proteins, which interfere with various cellular pathways. As 
a result of evolutionary pressure exerted by continuous exposure to viruses, each 
cell is equipped with a range of restriction mechanisms counteracting viral activity.  
After the successful binding of the gp120 and gp41 complex to the CD4 molecule 
and one of the co-receptors, the envelope of the virus can fuse with the cell 
membrane and enable the capsid core to enter the cell. The capsid then undergoes 
uncoating which frees genomic RNA, enzymes and other proteins required for 
initiation of the reverse transcription [30], [31]. The infected cell attempts to 
hamper this process with the use of TRIM5α molecules. Initially, it was speculated 
that this process could be based on an inhibition of decapsidation, but new evidence 
has shown that it actually promotes premature disassembly of viral capsids and thus 
restrict productive reverse transcription [32]. In humans, the levels of inhibition of 
virus replication due to the TRIM5α is relatively low whereas in non-human primates 
this mechanism seems to be much more effective [33]. In light of the murine HIV 
model described below, it is worth noticing that Fv1 restriction of MLV in mouse 
cells, which is known to involve different mechanisms than TRIM5α, also targets 
decapsidation [34], [35]. Productive uncoating is required for the initiation of 
reverse transcription of the viral genomic RNA to DNA. This process is conducted 
with use of an RNA-dependent DNA polymerase, which is simply called RT. RT was 
carried together with RNA in the capsid of the virus. After the initiation of reverse 
transcription a RNA/DNA molecule is generated on a RNA template. The RNA part is 
degraded and after a few more modifications, a second strand of DNA is transcribed. 
In addition to the RT polymerase lacking proofreading capacity, it can jump from one 
strand of the template to another, creating new recombinant virus variants [36]. In 
myeloid cells infected with HIV, the reverse transcription process is being disrupted 
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by the SAMHD1 protein. SAMHD1 inhibits RT productivity by depleting the pool of 
nucleotide triphosphates available in the cellular matrix [37]. Another RT 
counteracting mechanism involves the APOBEC3 family of proteins. Their role as a 
restriction factor is also based on indirect inhibition of RT activity. APOBEC3 
deaminates cytosines in the minus strand of the newly synthesized viral DNA 
transforming them into uracil. This leads to mutations in the provirus itself and uracil 
is recognized by the cellular DNA repair system. The unpaired DNA strands 
containing it are being degraded. Interestingly, APOBEC3 proteins need to be 
present during the infection. Therefore, they are packed together with the virus 
proteins into the capsid of the newly formed virus and acts on the next infected cell 
[38] [39], [40]. Vif is the main viral protein counteracting the activity of APOBEC3 
proteins. It triggers degradation of APOBEC3 by the proteasomal pathway. 
Therefore, the antiviral activity of APOBEC3 can play a substantial role only during 
infection with vif-defective or vif-deficient strains of the virus [41].  
Freshly transcribed viral double-stranded DNA is transported to the nucleus as a pre-
intergation complex. Viral integrase clips open chromosomal DNA and after 
modification of the 3’ ends of the viral DNA, it inserts it to the host cell chromosome 
[17]. Newly integrated viral DNA is being transcribed by host cell RNA polymerase II 
and the production of new virus particles can begin. HIV regulatory proteins are the 
first ones to be synthetized. Their role is to steer the production of new virus 
particles and counteract other restriction mechanisms. To enhance the transcription 
of virus RNA, Tat protein interacting with other host cell proteins binds to the LTR’s 
of the integrated virus DNA and severely enhances this process [42]. Transcribed 
RNA is either spliced and translated into proteins, or is destined to be loaded as 
genomic RNA into newly produced viral particles. To allow the unspliced mRNA to be 
taken out of the nucleus, another HIV protein, Rev, binds to the RNA and acts as a 
transporting chaperon [43], [44].  
In the view of murine models of HIV infection, it is worth noting that the inability to 
sustain Rev and Tat activity is regarded as one of the main obstacles in producing 
progeny virus by transformed murine cell lines. It was shown that in the 3T3 murine 
fibroblast cell line, Tat requires presence of human cyclin T1 for proper functioning 
and Rev depends on human p32 splicing inhibitor [45], [46]. However, in rat 
fibroblast cell lines, Tat mediates efficient transactivation and Rev activity is also not 
impaired [47]. The same can be seen in primary murine cells with chimeric virus in 
vitro and in vivo. Therefore it seems that mechanism Tat mediated transcription is 
facilitated by other murine protein or proteins and is yet to be described [48], [49].  
Nef is another HIV protein taking part in reorganization of cellular signaling and 
trafficking. Similarly to the other viral proteins it plays more than one role. Nef 
together with Tat and Rev is responsible for boosting the production of virus 
proteins, but the main role of Nef is to downregulate expression of MHC class I and II 
molecules. By this activity Nef protects the host cell from being recognized by the 
immune system long enough to ensure robust progeny virion production [50].  
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Once all the required proteins and unspliced RNA are synthesized and reach optimal 
concentration in the cell, the assembly of the new virions can begin. The gp160 
precursor is being cleaved by the furin proteases into gp120 and gp41. After 
reaching the cellular membrane, trimers of both proteins form a complex. Under the 
membrane surface, Gag p55 and Gag-Pol proteins, together with two ssRNA 
molecules, interact with the membrane embedded gp120-gp41 trimers and as newly 
formed virions bud out of the cell surface. Final modifications are made after 
budding. A HIV protease, retropepsin protease (PR), is being cleaved from the Pol 
precursor and cleaves Gag and Pol proteins into p17, p24, p7, p6, RT and IN proteins 
[43]. The host cell intends to interfere with the last steps of virus production. 
Membrane protein Tetherin (CD317) binds the newly produced virions to the cell 
and cross-links them with each other, thereby inhibiting their release. However, the 
HIV protein Vpu binds and inhibits Thetherin activity. Vpu induce CD317 
ubiquitination followed by proteasomal degradation. In the same manner, Vpu is 
responsible for down regulation of CD4 molecule expression on the cell surface [32].  
1.2.2.3 Cellular aspects of HIV latency 
Latency is typical for many viruses, bacteria and other infectious agents, but the 
characteristics are different for each one of them. Latency was initially described as 
a state of dormancy and was clearly distinguished from the chronic infection with 
persistent symptoms. With the progress of modern medicine and molecular biology, 
the line between latency and chronic infection has become very fine and they should 
be used mainly in describing clinical manifestations of the disease.  
In the case of HIV infection, a state of latency can be defined at three different 
levels: clinical, systemic and cellular. From the clinical viewpoint, it usually takes 
several years for the infected individual to develop noticeable symptoms. Therefore, 
on this level we can talk about true latency. On the contrary, on the systemic level, 
HIV never really enters the latent stage and the virus is constantly present and 
replicates in the host, mainly in activated T-cells [51]. Despite a virus-specific 
immune response, the virus can replicate, exceeding 1 billion particles per day in 
production rate [52]. Even during HAART therapy, viral levels are low but still 
detectable in the peripheral blood and lymphoid tissues [53–55]. 
Although all infected cells can become reservoirs of the virus, mainly CD4+ T-cells 
play that role. A pool of infected and activated CD4+ T-cells turn into memory cells 
establishing a potential viral reservoir that lasts for life [56].  
On the cellular level, the development of latency depends on the virus DNA being 
integrated or not into the genomic DNA of the host cell. In most cases HIV DNA, 
freshly transcribed from genomic RNA, does not integrate and resides in the 
cytoplasm. This state, called pre-integration latency, is abundant in cases of patients 
with viremia and in individuals which are not treated with ART. Pre-integration 
latency is found mainly in resting T-cells [39],[57]. Most of the non-integrated DNA is 
not replication-competent, is easily degradable by the host cell and is almost 
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undetectable after the course of ART [58]. The main form of virus cellular latency, 
which allows HIV to be so successful in establishing persistent infection, is stable 
integration into the genome of the host called post-integration latency or proviral 
latency. Although the frequency of the latent, replication competent integration is 
very low (not exceeding 1 in 10
6
 cells) in combination with extremely long half-life of 
the memory cells, it allows for lifelong infection. Additionally, the reservoir of 
infected memory cells can be replenished by ongoing low-level replication of the 
virus and infection of new cells [52]. The mechanism explaining why some proviruses 
become latent is not fully understood, but it is closely related to the site in the host 
genome in which the virus integrates and the state of activation of the host cell. It is 
known that the virus preferentially integrates into the introns and that high level of 
transcription requires LTR regions to be easily accessible for cellular transcription 
factors. In case of latently integrated provirus, reactivation begins the moment the 
cell is reactivated. Nuclear factor of activated T-cells (NF-AT) and NF-kappaB 
upregulate gene expression, which leads to Tat production and together with 
cellular factors transcription of viral RNA can begin [59]. Rearrangement of 
chromatin by histone deacetylases can also lead to the reactivation of latent 
provirus transcription [60]. Since patients still harbor the virus even after several 
years of HAART, understanding the processes of entering and exiting proviral latency 
are of great importance for improving the outcome of the therapy. Because immune 
activation plays a key role in reactivation of provirus transcription, several attempts 
have been made to boost that process and thus improve the efficacy of HAART. 
Most of the studies have been based on administration of IL-2 alone [61], or with 
IFNγ or anti-CD3 activating antibodies [62], [63]. In the first weeks after treatment 
begins, the levels of viral RNA in plasma drop significantly and T-cell activation is 
increased. Regrettably, the levels of HIV RNA rebound within weeks after therapy 
was halted. To purge the reservoir of latently infected memory cells, 
cyclophosphamide was used together with HAART. It resulted in the elimination of 
infected and non-infected cells without any impact on the viral levels [64]. Also, 
therapy with valporic acid, which act as a HDAC inhibitor, inducing relaxation of 
chromatin and therefore activation of provirus transcription has not been successful 
[65]. It is unlikely that without tackling the issue of the latently infected memory cell 
reservoir ART therapies will be successful and achive complete HIV clearance. 
Additionally those treatments can have a deteriorating impact on the already 
strained control of latent TB in TB/HIV co-infected individuals. 
1.2.3 HIV transmission 
HIV can be transmitted in various ways (intravenous, mother-to-child transmission, 
anal intercourse, etc.) but the major route for infection is through genital mucosal 
surfaces during heterosexual intercourse. Due to the protective environment of the 
genital tract being able to neutralize the majority of viral particles, the risk of being 
infected is less 1:500, although women are twice more likely to be infected than 
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men. For heterosexual intercourse, more than 80% of infections are caused by only 
one single virus breaching through the mucosal defenses. For other routes of 
infection the risk is significantly higher. For example, in the case of iv transmission, 
the risk is almost almost certain [66],[67].  
Free and cell bound virus can be found in the semen and vaginal secretions, and 
both forms were shown to be infectious, which indicates that virus transmission 
through the mucosa can be achieved by different means [68]. Understanding those 
mechanisms is crucial for the development of blocking agents, vaccines and 
therapies. Studies done with SIV infections indicate that although the first cell to be 
productively infected are CD4+ T-cells, it is DCs that are responsible for transmission 
of the virus through the mucosa [69]. Since the mucosal secretions and mucosal 
associated immune cells are the main barrier for viral entry, any disturbance in this 
environment caused by other infections like HSV2 or Neisseria leads to a higher risk 
of HIV transmission [70].  
1.2.4 Development of infection 
After successful transmission the initial stage of viral infections begins. Within a 
week, detectable amounts of viral particles appear in plasma, followed by robust 
viremia lasting for a few weeks. After that time, the viral loads peaks at 10
7
 particles 
per ml of plasma and the virus widely disseminates and spreads in the body, 
including to lymphoid organs [71]. Although viral particles circulate in the whole 
system, the majority of infected T-cells are located in the GALT [43],[21]. After 6-8 
weeks, virus-levels begin to decrease. It can be attributed to the developing immune 
response directed towards the virus. Probably already at this point, a pool of CD4+ 
T-cells is already substantially diminished [72]. Early control of the infection is 
associated with the generation of HIV-specific CD8+ T-cells and high antigen-specific 
CD8+ T-cell numbers correlate with better clinical predictions for the latent phase 
[73], [74]. In CD8+ T-cell depletion studies, rhesus macaques infected with SIV had 
several times increased viral plasma levels, which indicates that cytotoxic T-cells play 
a critical role in controlling virus replication [75], [76]. Although cytolysis plays a 
major role in maintaining viral control and expression of cytolitic enzymes closely 
correlates with viral control, cytotoxic T-cells also employ non-cytolytic mechanisms 
to suppress viral replication. Studies on macaques have demonstrated that secretion 
of IFNγ, MIP-1β ,IL-1α and TNF strongly suppressed virus replication, but decreased 
significantly in CD8+ T-cell depleted animals [77–80]. Consequently, viral inhibition 
mediated by cytotoxic cells is mediated by numerous factors with various effector 
mechanisms. Polyfunctionality of CD8+ T-cells is characterized by simultaneous 
production of many effector molecules, usually three or more. The most widely used 
markers associated with antiviral activity of cytotoxic cells are IFNγ, TNF, IL-2, MIP-
1β and perforin. Although correlation of expression does not prove causality, it is 
clear that individuals harboring more polyfunctional CD8+ T-cells are better in 
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controlling virus replication [81–83]. In a recent vaccine study, the antiviral activity 
facilitated by CD8+ T-cell was dependent on IFNγ-production only when IFNγ was 
expressed together with MIP-1β and CD107a (a marker for degranulation) [84]. IL-2 
and TNF were also shown to correlate with virus control in elite controllers and long-
term non-progressors [85]. Because of the complexity of the cytotoxic T cell 
response, and the fact that it is constantly changing due to the emergence of 
cytotoxic T cell escape variants, it is very difficult to pinpoint which molecules are 
crucial for virus control. Also, it is not known if the co-expression of several effector 
functions are required to control viral replication, or if polyfunctionality is only a 
marker that correlates with successful viral suppression. Importantly it is now clear 
that a higher percentage of polyfunctional CD8+ T-cells correlates with higher CD4+ 
T-cell counts. Additionally, expression of perforin by cytokine-producing cells was 
demonstrated to correlate with better virus control. Unfortunately, unlike perforin, 
cytokine polyfunctionality of CD8+ T-cells by itself was not associated with lower 
virus burden [78]. 
Cytotoxic T-cells isolated from HIV-viremic patients can inhibit replication of the 
virus in vitro, and thus show that they are functional and specific. Nevertheless, 
cytotoxic responses are unable to completely stop dissemination of the virus and 
clear all of the infected cells. This is due to the genetic diversity of the virus, which 
contribute to constantly create new escape virus variants, as well as to the virus 
entering post-integration latency. Escape from the cytotoxic activity of CD8+ T-cells 
is limited by fitness cost to the virus and conserving functionality of vital viral 
components. This results in some regions of the HIV genome being more conserved 
than others and emergence of conserved epitopes [86]. Additionally, recently it has 
been shown that CD8+ T-cells can recognize epitopes derived from alternate reading 
frames. During early SIV infections, those products are recognized by more than 20% 
of cytotoxic T cells and their recognition is persistent trough the course of infections 
[87], [88]. 
After the initial viremia diminishes the clinical latency period begins. Although the 
infected individuals do not show any symptoms of the disease, it is not a passive 
stage in terms of replication of the virus and response of the host immune system. 
During the next few years after infection, the virus is constantly present in its free 
form in the plasma. The immune system is constantly activated and the CD4+ T-cell 
count, after partial recovery in the first few months, continue to go down until it 
reaches <350 cells per microliter, which is considered to be the beginning of AIDS. 
For every individual, the period between the control of viremia to manifestations of 
AIDS depends on personal genetical characteristics, environmental factors, co-
infections with other pathogens and the state of the immune system [52], [89–93]. 
One of the factors, which are thought to be critically contributing to the progress of 
the decay of immune system, is the chronic immune activation observed during the 
latent phase. Chronic activation manifests itself as an increased level of pro-
inflammatory cytokines, prolonged expression of lymphocyte activation markers and 
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increased turnover of the lymphocytes themselves [94–96]. The level of T-cell 
activation measured as CD25 or CD38 expression correlates closely with CD4+ T-cell 
counts and T-cell [97], [98]. This can be observed even in patients receiving ART 
treatment and in elite controllers [99].  
1.2.5 Decay of the immune system during HIV infection 
1.2.5.1 Chronic immune activation and immune exhaustion 
Other aspects of chronic activation of the immune system during HIV infection are 
that the replicative capacity and the quality of T-cell activation by APCs resemble 
that of an aged person. One of the features associated with this process is reduced 
expression of the CD28 marker on the surface of T-cells. CD28 is instrumental in 
activating naïve cells by binding to CD80/CD86 on the surface of APC during antigen 
presentation. Loss of CD28 occurs naturally during the lifetime and it is associated 
with inability to respond to vaccinations and greater susceptibility to infections in 
older age. Not only is the ability of the cells to become activated impaired, but they 
are also more prone to apoptosis [100], [101].  
Exhaustion of the immune system also transpires in increased expression of 
inhibitory markers on T-cells, like cytotoxic T-lymphocyte antigen 4 (CD158), 
programmed cell death (PD1) and newly described in contexts of HIV infection T cell, 
immunoglobulin and mucin domain-containing molecule-3 (TIM3) [102], [103]. 
Studies where CD158 was blocked by anti-CD158 antibodies have shown no 
advantageous effects, but when PD1 was inactivated in a similar manner T-cell 
responses were partially restored [104]. In animals infected with SIV inhibition of the 
PD1 pathway was followed by a decrease in the virus load and improved survival 
rate [105]. PD1 upregulation is also associated with increased spontaneous and Fas-
mediated apoptosis of cytotoxic and helper T-cells [106–108]. TIM3 is another 
inhibitory molecule that is found on the surface of exhausted cells. It is known that 
due to immune exhaustion T-cells lose their capacity to produce proinflamatory 
cytokines step by step. First, IL-2 production is impaired followed by loss of TNF and 
finally IFNỵ [109]. 
In the early phase of infection, TIM3 is expressed on the cells producing IFNỵ but not 
TNF. TIM-3 is believed to inhibit Th1-mediated immunity and promotes peripheral 
tolerance[110], [111]. During the latent phase of HIV infection, TIM3 co-expressed 
with PD-1 is considered one of the best markers of exhaustion and correlates with 
reduced number of CD4+ T-cells and increased viremia. Similar to PD-1, when Tim-3 
signaling was blocked, both cytotoxic and helper T-cell proliferation and 
functionality was improved [103]. 
Interestingly the level of inhibitory receptor expression is not only dependent on the 
stage of the chronic infection, but also on the specificity toward different antigens. 
PD-1 expression was compared on the CMV- and HIV-specific CTLs from the same 
patient. Surprisingly, higher cell surface levels of PD-1 were detected on HIV-specific 
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T-cells when compared to CMV-specific T-cells. After administration of ART therapy 
the levels were comparable between CMV- and HIV-specific T-cells [112]. 
1.2.5.2 Microbial translocation 
The level of T-cells activation go hand in hand with the phenomenon called microbial 
translocation. Early after infection, the majority of infected CD4+ T-cells are located 
in GALT. CD4+ T-cells by Production of inflammatory cytokines by CD4 cells as well as 
processing and cross-presentation of antigens derived from apoptotic bodies from 
dying CD4 cells recruits CD8+ cytotoxic cells to the site [113], [114]. Although 
epithelial cells are not infected with the virus, the increased numbers of perforin-
expressing CD8+ T-cells seem to contribute to the mucosal damage in the gut during 
the acute phase of infection. Dramatic reduction in the number of resident CD4+ T-
cells, and a decrease in the quality of the protective mucosal layer, results in leakage 
of microbial product [115]. Although the damage to the mucosa is done mainly 
during the acute phase of infection, elevated levels of bacterial LPS in the system are 
detected throughout the course of the disease. In addition, it correlates with the 
progressive decrease in the CD4+ T-cells count [116]. Even after beginning of ART 
treatment the levels of LPS are elevated comparing to non-infected individuals. This 
leads to constant activation of monocytes, macrophages and CD4+ T-cells 
[117][118]. 
1.2.6 Humoral responses  
Although HIV does not directly infect B-cells, the B-cell response is severely affected 
during HIV infection. Cellular immunity is thought to be a prevailing factor in 
immune response against HIV infection. Still, antibodies allow for neutralization of 
new progeny virus particles and facilitate induction of antibody dependent 
cytotoxicity, phagocytosis and activation of complement [119]. Antibodies against 
the virus, produced during first few weeks of the immune response, have low or 
non-neutralizing ability. Even though Ab against neutralizing epitopes emerge later 
on, new escape variants constantly emerge due to the high mutation rate of the 
virus [120]. Despite that, some individuals are able to produce broadly neutralizing 
antibodies (NAbs). Unfortunately, those Ab are generated in the chronic, not the 
acute phase of the infection. For some time, the ability to elicit NAb by vaccines 
candidates was considered to be of less importance during preclinical testing as 
compared to strong cellular responses. Animal studies have demonstrated that 
partial protection can be achieved with passive administration of anti-HIV NAbs, 
showing the benefit of a strong hummoral response [121]. Additionally, individuals 
being able to produce Nabs displayed a reduced virus load in plasma, which lowers 
chances of virus transmission. For example, in macaques which could elicit moderate 
plasma levels of Nab more vaginal challenges were needed to achieve infection than 
in the control group [122], [123]. Although HIV does not infect B-cells, it affects their 
functions, maturation and the memory compartment. Chronic activation of the 
immune system also leads to hyper-activated B-cells and hypergammaglobulinemia 
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is observed in HIV-infected patients [119], [124]. B-cell exhaustion can be observed 
as the disease the progresses. Although plasma levels of circulating IgG Ab are high, 
B-cells isolated from infected individuals display impaired capacity to produce Ab in 
vitro and the percentage of B-cells having a memory phenotype is lower [122], [124], 
[125]. Normal levels of memory B-cells are restored after HAART has been 
administrated, but the B-cells are still more prone to Fas-mediated apoptosis [125]. 
This phenomenon is not HIV-specific and humoral responses against other 
pathogens, like tetanus or measles are being impaired as well, including the level of 
antibody production and sustained B-cell memory [126]. 
1.2.7 Long-term non-progressors and elite controllers 
A distinctive group of seropositive individuals was identified who despite being 
infected with a pathogenic strain of the virus are not progressing towards AIDS. 
Furthermore, the so-called long-term non-progressors, are maintaining the CD4 
count on a relatively high level for prolonged periods of time. Other patient groups 
can keep virus replication in control even to the point when the virus is undetectable 
in serum (controllers and elite controllers). These groups develop stronger than 
average CD8+ T-cell responses, especially toward gag epitopes [82], [93], [127]. 
However, in studies done by Sáez-Cirión et. al. five elite controllers, constituting for 
25% of the study group, had no CD8+ T-cell-mediated responses [128], [129]. This is 
an example of how complex and individualistic the successful immune response 
toward the virus can be. This is important in the context of screening new vaccine 
candidates, where what is now considered a signature of protective immunity in the 
future can be shown to be an artifact of an irrelevant correlation.  
1.2.8 HIV Animal models  
Due to the host-range restriction of HIV, it is challenging to establish suitable models 
for viral infection and anti-viral immune responses. Although chimpanzees are 
naturally susceptible to HIV infection, they are usually not used as laboratory 
animals because of ethical and economic reasons [130]. Instead, smaller non-human 
primates, like Cynomolgus or Rhesus macaques, took their place. Unfortunately, the 
further away that we move from homo sapiens on the evolutionary tree, the more 
discrepancies can be seen between human immune responses and those of other 
primates. Species-specificity of HIV does not allow for infection of macaques. 
Therefore, various closely related viruses are used instead of HIV. SIV is closely 
related to HIV and naturally infects sooty mangabeys monkeys. Despite the high 
levels of viremia in sooty mangabeys, SIV is non-pathogenic. If macaques are being 
infected with SIV they can develop AIDS-like syndromes (sAIDS – simian AIDS). To 
overcome the differences between SIV and HIV, especially in vaccine studies, 
genetically modified chimeric viruses have been constructed with various ratio of SIV 
and HIV genetic material [130–132]. To lower the cost and shorten the time of the 
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studies, highly pathogenic strains of the viruses are usually used. For example, 
SHIV89.6P infection of macaques results in rapid decline of the CD4+ T-cell count 
and progression to sAIDS in months instead of years [133]. The use of chimeric 
viruses has proved to be one of the most useful tools in vaccine discovery despite 
their lack of some HIV components, for example envelope protein.  
Several approaches have been made over the years to develop a murine HIV model 
and the main focus has been on genetically modified mice in which the murine 
immune system has been replaced with human components. Other strategies have 
involved adapting the virus to be able to infect murine cells. Soon after the discovery 
of HIV, the first attempts were made to replicate the virus in murine cell lines and in 
mice expressing the human CD4 receptor and other co-receptors [134], [135]. 
Unfortunately, no infectious virus progeny was produced by murine fibroblast cell 
lines and the infection of transgenic mice was very limited. Consequently, it seem 
that there is a strong murine restriction not only on the level of viral entry into the 
cell [136]. Therefore, another approach to establish a productive HIV infection in 
mice was to substitute components of the murine immune system with their human 
counterparts. After total body irradiation, mice were transplanted with human bone 
marrow and human lymphocytes. This allowed for a short-term and limited study 
spectrum of antibody immunity against the virus in vivo [137], [138]. Mice with 
severe-combined immunodeficiency (SCID) could be used as recipients of a human 
tissue engraftment. In SCID animals B- and T-cell receptor genes are mutated which 
result in a defective B and T-cell phenotype [139], [140]. Two models of engraftment 
in SCID mice have been widely used. In the SCID-hu thy/liv model, fragments of fetal 
liver and thymus are transplanted into a SCID mouse, whereas in the (hu)–SCID-
huPBL model, peripheral blood mononuclear cells (PBMCs) isolated from cord blood 
or from healthy donors are injected intraperitoneally [141], [142]. The two models 
have been used mainly to study the cytophatic effect of the virus and for 
antiretroviral drug development, but are not really suitable for long-term studies of 
pathogenesis or vaccine efficacy [140], [143]. Currently, new SCID humanized 
models depend on engraftment of presorted CD34+ heamatopetic stem cells, 
derived directly from fetus liver, cordial blood or isolated from adult donors PBMCs 
after GM-CSF treatment which induce release of stem cells from bone marrow. The 
majority of cells that develop after the reconstitution are B-cells and T-cells although 
NK cells and myeloid cell subsets may also be present. After CD34+ engraftment, the 
animals develop both primary and secondary lymphoid organs. Although these 
models present impressive step toward developing a working human immune 
system in a rodent, the functionality of the immune cells, their localization, 
numbers, ratios, and interaction with non-hematopoietic cells and host-derived 
factors are problematic [144–146].  
The reversed approach to develop a murine model of HIV infection is to circumvent 
the CD4-dependent viral entry into host cells. The main advantage of this approach 
is that it enables the use of conventional, immunocompetent wildtype mice.  
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Several attempts have been made to genetically modify HIV that would allow it to 
effectively bind to murine cell surface receptors. One of the early models, developed 
at Karolinska Institutet, is based on the generation of random chimeric viruses from 
murine leukemia virus (MuLV) and HIV. In short, human CEM line cells carrying the 
complete genome of the MuLV virus are infected with HIV and produce four 
different types of viral particles: MuLV, HIV, MuLV carrying the HIV genome and HIV 
carrying the MuLV genome. Next, activated murine spleenocytes are infected in vitro 
with a virus mixture and then injected intraperitoneally into recipient mice. Cells are 
only infected with MuLV enveloped viruses of which a small fraction contain the full 
HIV genome. After several days the cells are recovered from the peritoneal cavity 
and co-cultured in vitro with a HIV reporter cell line to assess the ability of recovered 
cells to produce infectious HIV particles [147], [148]. This method allows for a crude 
assessment of HIV antigen-specific cytotoxic response in the mouse and proves that 
murine cells can produce viable HIV particles, if limitations to the virus entry are 
circumvented. However, it does not establish a productive, self-sustaining infection.  
Potash and colleagues developed a similar approach of utilizing a MuLV/HIV 
chimeric virus [48]. Instead of relying on random generation of chimeric viruses, 
Potash et al constructed two Eco models, EcoHIV and EcoNDK, in which a fragment 
of the env gene in HIV genome was substituted with the env gene coding gp80 from 
ecotropic MuLV virus. The HIV backbone of the constructs were either the common 
laboratory strain NL4-3 (clade B), or the highly pathogenic isolate NDK (clade D) [6], 
[149]. Chimeric viruses created this way are able to infect, and successfully replicate 
in, murine cells but not in human cells. Because the gp120 envelope protein is 
substituted with gp80 from MuLV, tropism of the chimeric virus is the same or 
similar to the MuLV virus. The receptor for MuLV virus is a cationic amino acid 
transporter (mCAT-1) protein which is expressed mainly on hematopoietic cells but 
can also be found on other cell types, including epithelial cells [150], [151]. The 
highest concentration of mCAT-1 expression in tissues correlates closely with the 
level of EcoHIV replication. High virus levels are detected in testicles, thymus, spleen 
and peritoneal macrophages. Although mCAT-1 is quite prevalent in lymph nodes 
and lungs EcoHIV is not preferentially replicating in those tissues [unpublished data]. 
In in vitro cultures, EcoHIV has been shown to be able to infect 10% of activated 
spleenocytes but failed to replicate in cell lines, i.e. 3T3 embryonic fibroblast cell line 
despite the presence of the mCAT-1 receptor [49]. Both EcoHIV and EcoNDK were 
shown to be able to establish a systemic infection in approximately 80% of 
inoculated animals and can be detected fro several weeks after infection [48], [152]. 
Importantly, from the perspective of vaccine studies EcoHIV infection is broadly 
disseminated and induces HIV-specific immune responses [153], [154]. Because of 
the ability of this virus to establish a persistent infection in WT mice we decided to 




1.2.9 HIV vaccines 
1.2.9.1 Early attempts – live attenuated and inactivated vaccines  
From clinical, epidemiological and economical points of view, vaccines are the most 
effective way of preventing the spread of infectious diseases. No other therapeutic 
or preventive approach will allow for a complete eradication of the disease. The first 
vaccine ever administered was a crude preparation of non-pathogenic cowpox virus 
that elicited protection against the closely related, but lethal, smallpox virus. 
Although the mechanisms of protection achieved with this approach were not 
understood for more than a century, it has been proven over the following years 
that even the most dangerous human infections can be successfully prevented. After 
a rigorous campaign of vaccination, smallpox was eventually officially eradicated. 
Since then, developing a protective vaccine became the ultimate goal of research on 
every infectious disease [155].  
The sterilizing vaccines that have been developed to date are mainly based on live, 
attenuated strains, or variants of the pathogenic agent, or on killed or inactivated 
microorganisms. Live attenuated vaccines were developed essentially against viral 
infections (polio, measles, mumps or yellow fever). Generation of such vaccines 
from the current perspective appears to be easy and strait forward. A pathogenic 
virus is passaged several times through cell cultures to minimize its pathogenicity, 
even though it may still be able to replicate to some extent in host cells. Similarly, a 
closely related, naturally occurring strain can be used (chickenpox). Usually, causing 
asymptomatic or mild infection, live attenuated vaccines are able to initiate both 
humoral and cellular adaptive immune responses without requiring additional 
stimulus such as adjuvants. This is a major advantage over the other types of 
vaccines [156].  
This strategy was adapted in early preclinical vaccine trials against HIV. Monkeys 
infected with a nef deficient SIV virus were temporarily protected against an i.v. 
challenge with fully functional SIV [157]. Unfortunately, the mutation rate of the 
virus was so high that after several months of controlled infection, non-pathogenic 
nef-deficient strains mutated and created a virulent form of the virus which caused 
immune degeneration [158]. The same phenomenon was observed in patients 
infected i.v. during blood transfusions with a nef-deficient HIV strains [159], [160]. At 
the moment, HIV attenuated strains are regarded to be too dangerous to be used as 
a vaccine, due to their extreme mutation capabilities. Another negative 
characteristic of live vaccines is that the replication competent viruses or bacteria 
can cause disease, especially in immune-compromised individuals, although the risk 
in general public is relatively low. One prime example is the use of oral polio vaccine 
(OPV) only in areas of high incidence, where a direct risk of vaccine-associated 
paralytic poliomyelitis (VAPP) caused by OPV strain is smaller than the chance of 
contracting the disease in a classical way. When the prevalence of polio drops, 
inactivated poliovirus vaccine (IPV ) administered by injection is used [161].  
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IPV represents another approach to generate vaccines by inactivating infectious 
strain of the virus or bacteria by physical means. Although several successful 
inactivated vaccines have been developed, they are inferior to the attenuated 
vaccines that are inducing broad protective immune responses. The inactivated or 
killed pathogens are not able to replicate. Therefore, immunization results in 
induction of strong humoral, but not cytotoxic T-cell mediated responses [162]. An 
inactivated vaccine candidate against HIV was tested. The Remune vaccine was 
constructed on the base of inactivated HIV particles stripped of the gp120 protein 
and formulated in incomplete Freund’s adjuvant [163]. When administered to HIV-
infected individuals, the CD4 counts increased and the virus levels in plasma 
decreased [164]. An alternative approach may be to administer Remune with the 
ALVAC vaccine in hope of prolonging low viral levels in plasma during periods of 
HAART therapy interruption [165]. 
1.2.9.2 Recombinant vaccines. 
 Progress in molecular biology allowed the development of a new generation of 
vaccines by administration of purified antigens. This made it possible to develop a 
robust and very flexible composition of vaccines mainly based on proteins. 
Unfortunately, similarly to the inactivated vaccines, protein vaccines mainly induce 
antibody and helper T cell responses. Additionally, they are also unable to stimulate 
innate immunity via pathogen associated molecular patterns (PAMPs) which reflect 
the low ability of inducing long term memory. To circumvent this problem vaccine 
subunit are administered with immune stimulators called adjuvants which help to 
induce broader immune responses [162]. One of the few adjuvants used to boost 
subunit vaccine responses used in humans is hydrated potassium aluminum sulfate 
(alum). Despite the fact that alum has been used for decades, the exact mechanism 
of the immune stimulatory properties is not clear. It is believed that alum forms 
depots from which the vaccine is slowly released, causing inflammatory responses 
when recognized or phagocytosed by APCs. Recently it has been shown that 
stimulation of DCs by alum induce production of ureic acid, which when detected in 
tissues is known to be an endogenous danger signal that recruits and activates 
inflammatory monocytes and DCs [166], [167].  
Due to the risk associated with attenuated and inactivated strains, the new 
generation of HIV vaccine candidates are mainly vector or subunit vaccines. Because 
the latter induces mainly humoral responses the majority of the candidates are 
based on generating neutralizing antibodies against the gp120 protein, restricting 
virus entry into the cell. Several studies have also been conducted with the use of 
recombinant Gag and Tat proteins [168], [169]. The key obstacle in establishing 
protective immunity is the genetic variability of the virus, even when only the most 
prevalent and genetically conserved epitopes are being used.  
A promising study utilized recombinant gp120 as a vaccine in the AIDSVAX trial 
[170]. The first phase III trial was conducted mainly in North America with the use of 
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gp120 subtype B and enrolled 5000 uninfected participants. The second trial was 
conducted in Thailand with gp120 from subtypes B and E, and included individuals 
from high risk groups like i.v. drug users and sex workers. Despite very promising 
results for the earlier trials no protection was observed compared to the group 
receiving only adjuvant. Despite this drawback, AIDSVAX was used as a boost for the 
ALVAC trial which showed moderately positive results [171].  
1.2.9.3 Genetic vaccines 
 The latest and most promising approach to tackle the inefficiency of recombinant 
vaccines for intracellular pathogens is the use of genetic vaccines. By being 
expressed directly by the host cell, viral antigens can be presented to the immune 
system in the same manner as during natural infection and thus increasing the 
chances of eliciting protective immune responses. Genetic vaccines can be 
administered as purified DNA in an adjuvant formulation or carried as recombinant 
virus vectors, mainly based on poxviruses and adenoviruses [172]. 
The only vaccine candidate which has given promising results after a phase III clinical 
trial (significant protection, p=0,04) is a recombinant canarypox virus, carrying HIV 
env (subtypes B and E), gag and protease (subtype B) developed by Sanofil under 
the commercial name ALVAC. It was used in one of the biggest HIV vaccine placebo 
controlled trials, RV144, in which 16000 uninfected individuals were enrolled in 
Thailand. Claims that this trial was successful can be disputed, since the differences 
between the vaccinated and control group were modest. For example, the viral load 
in infected individuals did not differ between the patient groups. [165], [171].  
The significance of the ALVAC trial is even more clear when compared to the Merck 
STEP study, which had to be discontinued due to futility. Over 3000 uninfected 
individuals were enrolled in this study, 49 of the 914 men in the vaccine group got 
infected with HIV when compared to 33 men of 922 in the placebo group. Since the 
vaccine candidate was based on the adenovirus vector (Ad5) carrying gag, pol and 
nef genes of HIV it was speculated that pre-existing immunity to Ad5 could be to 
blame. Although no association could be found, it has lowered the level of 
confidence in the safety of adenovirus-based vectors [173–175]. 
One of the ways to overcome the pre-existing immunity toward the vector is 
administration of the vaccine in its pure DNA form. Additionally advantages are easy 
manufacturing, stability and flexibility of this system. DNA immunizations are highly 
antigen specific, but are unable to elicit strong response by themselves. Therefore, 
the vaccine candidate needs to be administrated together with adjuvants and in 
prime-boost regimens. Nevertheless, DNA vaccines are able to stimulate innate 
immune responses much better than protein subunit vaccines. Because plasmid 
vectors are propagated in bacteria they carry unmethylated cystidine-phosphate-
guanosine (CpG) motifs which stimulate toll-like receptor 9 (TLR9). DNA-dependent 
activator of IFN regulatory factors (DAI) and the TANK-binding kinase-1 (TBK-1) also 
activate innate immune system after recognizing plasmid double stranded DNA 
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[176–178]. Adjuvants not only facilitate strong stimulus for the immune system, but 
also play a role as carriers of the vaccine, they enhance phagocytosis as well as 
protect the vaccine from premature degradation. In DNA vaccine formulations one 
of the most efficient adjuvants are lipid emulsions in the form of liposomes, or more 
complex nano- and microparticles which bind DNA and by neutralizing the charge of 
the plasmid enhance transport of DNA across the cell membrane [179]. Emulsions 
are used to augment humoral responses also in protein based subunit vaccines. The 
oldest and most commonly used emulsion in laboratory setting is mineral oil based 
Freund’s adjuvant. However, new adjuvants based on squalene have been recently 
developed and are now used commercially: MF59 by Novartis and AS03 by 
GlaxoSmithKline [180], [181]. In study III we have successfully used two new 
adjuvant formulations 2% mono-olein and oleylamine (N3) for DNA prime and 2% 
mono-olein and oleic acid for protein booster formulation (L3).  
To further improve DNA-based vaccinations, a regimen of prime and boost has been 
adapted where usually the prime is delivered in form of DNA followed by one or 
more recombinant protein, or viral vector, boosts (as described earlier). It has been 
demonstrated that highly specific cytotoxic and humoral immune responses elicited 
by a DNA vaccine can be significantly enhanced by protein boosts [182], [183]. The 
efficacy of a DNA prime-boost strategy was shown in the study of a recombinant 
modified Vaccinia Ankara virus (MVA) vaccine candidate carrying the HIV genes env, 
gag and pol, which was developed at Karolinska Institutet. When the vector was 
administrated alone it induced only moderate immune responses, mainly against 
envelope protein, but after the introduction of a DNA prime – vector boost regime, 
it became highly immunogenic for gag and env epitopes [184]. In the RV144 trial, 
another prime-boost regimen was adapted by boosting vector prime (ALVAC) with 
protein formulation (AIDSVAX). Encouraging results from this study provide 
convincing arguments in favor of combining genetic and recombinant vaccine 
candidates [185]. 
To further enhance the potency of DNA-based vaccines various ways of delivery are 
being explored. Vaccines can be injected intradermally (i.d.) or intramuscularly 
(i.m.), or administered at mucosal surfaces (intranasally, intravaginally, etc,) or 
delivered with gene gun or electroporated directly into the tissue [186]. Different 
ways of delivery of the same vaccine can modulate quality and scale of the immune 
response (as shown in Paper III). 
Taken together, various ways of constructing genetic vaccines, combined with 
different delivery methods and adjuvants provide a vast spectrum of accessible 
solutions for the problems we face with vaccine development against HIV. Although 
a vaccine providing sterilizing immunity will probably remain elusive for a long time, 
improving quality of the acute immune response to the virus by vaccination can 
have a significant impact on the resolve of the epidemic by reducing the 
transmission by highly viremic patients and therefore slowing down infection.  
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1.3 MYCOBACTERIUM TUBERCULOSIS (MTB) 
1.3.1 Structure and genetic diversity  
MTB is a microaerophilic, rod shaped bacteria. Unlike other bacteria, the MTB cell 
wall contains significant amounts of lipids (60%), which determine resistance to 
conventional staining (such as the Gram staining). It can also be visualized after 
staining with the Ziehl-Neelsen method. After a classical staining of all bacteria with 
fucsin, other bacteria in the culture are discolored with 3% HCl solution in ethanol, 
whereas mycobacteria retain the pigment. Hence, mycobacteria are commonly 
referred to as acid-fast bacilli (AFB). The mycobacterial cell is composed of complex 
macromolecular polymer containing peptidoglycan, arabinogalactan and mycolic 
acids, which makes it unique among other bacterial species. It plays a critical role 
both as an impermeable barrier and in bacterial virulence. The mycobacterial cell 
undergoes dynamic architectural modifications during infection that correlate with 
both the active and the dormant state [187], [188]. When in a dormant form, due to 
its cell wall, mycobacteria can resist many different environmental factors such as 
desiccation, elevated and low temperatures, high and low pH. Interestingly, it can 
persist in the environment for a long time while still being infectious. One of the 
main physiological characteristics of MTB is an average division time of 15-20 hours, 
which results in particularily long culturing time (a colony which could be visible to a 
naked eye requires over 3 weeks of culture on solid media).  
Mycobacterial strains that are human pathogens are usually described as belonging 
to the MTB complex consisting of several closely related species with minimal 
genetic variation and includes Mycobacterium tuberculosis (MTB), Mycobacterium 
canettii, Mycobacterium africanum, Mycobacterium microti and Mycobacterium 
bovis, also as attenuated vaccine strain M. bovis bacille Calmette-Guerin (BCG). MTB 
is a major pathogen in human populations. In contrast, other species are usually 
causing opportunistic diseases in immunodeficient individuals. Other pathogenic 
mycobacteria which do not belond to MTB complex are Mycobacterium leprae and 
Mycobacterium marinum [189].  
In 1998, the genome of the MTB H37Rv strain was sequenced. It consists of 4 million 
bps coding for 3,959 genes. Until now, only about 50% of the genes have been 
characterized. Since the genome was sequenced, comparative genomic studies have 
identified several MTB-specific genomic regions of difference (RDs) absent from the 
genome of avirulent BCG [190], [191]. The importance of this finding lays not only in 
the prospective analysis of virulence factors but also in the possibility of developing 
better diagnostic tools based on immunological readouts that are able to distinguish 
people latently infected with MTB from BCG-vaccinated individuals. The first 
discovered region - RD1, codes for the most studied proteins. Early secretory antigen 
6kDa (ESAT-6) and culture filtrate protein 10kDa (CFP-10) were identified as 
promising diagnostic antigens as well as possible vaccine candidates. Currently, 
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more than 11 RDs have been identified and the number of proteins that are being 
tested for their usefulness as diagnostic markers has incresased [192–194].  
Taking into account the importance and complexity of the mycobacterial cell wall, it 
is not surprising that more than 250 genes are found to be related to the 
metabolism of fatty acids and 40 are directly associated with the construction of the 
cell wall. These genes are highly conserved, demonstrating the evolutionary 
importance of the lipid wall for the survival of MTB [188].  
As a result of pressure exerted on HIV by the immune system, immense genetic 
variability occurs in a single host, which leads to constant development of new 
escape variants of the virus. In contrast, a recent study of MTB-derived human T-cell 
epitope diversity have shown that most prevalent epitopes recognized by the 
human immune system are also the most conserved elements of the MTB genome. 
The study included over 500 experimentally verified human T cell epitopes derived 
from a collection of geographically and genetically diverse isolates. The data suggest 
that at least some MTB-derived proteins do not change to avoid MHC-restricted T 
cell immunity. It is tempting to speculate that MTB may actually benefit from T cell 
recognition under some circumstances and provide an evolutionary advantage 
[195]. It has been suggested that MTB uses excessive inflammation caused by the 
immune response to generate tissue damage and lung cavitation, which promotes 
transmission of the bacteria. This demonstrates how complex and unique the host-
pathogen interactions are between infected humans and MTB. 
1.3.2 Transmission and cell entry  
Bacilli of MTB are transmitted via airborne person-to-person contact. Actively 
infected hosts cough and expell bacteria, which are then inhaled by another 
individual. Acute pulmonary TB is relatively rare since only about 10% of infected 
individuals develop disease symptoms. Primary TB pneumonia is most often 
diagnosed in young children, elders or in immunosuppressed individuals such as HIV-
infected and AIDS patients. In addition, it can also affect patients on long-term 
corticosteroid therapy. The most common forms of active disease are miliary and 
cavitary TB. In miliary TB many small nodules can be seen on a chest X-ray 
distributed throughout the lungs, whereas in a later form mainly highly oxygenated 
upper lobes are affected. Excessive immune reactions, necrosis of infected cells and 
remodeling of the connective tissue by the bacteria, cause destruction of the lung 
tissue and formation of large air pockets (cavities). This type of TB is highly infectious 
and occurs mainly during reactivation from latent TB [189]. After being inhaled and 
deposited in pulmonary alveoli, the bacteria are phagocytosed by alveolar 
macrophages, neutrophils, monocytes or DCs [196]. Due to the specific environment 
in which alveolar macrophages reside and the constant exposure to foreign airborne 
particles, these cells do not induce as strong inflammatory responses as 
macrophages in other tissues [197].  
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MTB does not have any active mechanisms of cell entry and this process is facilitated 
by receptor-mediated phagocytosis. There are two receptor families which mediate 
recognition and phagocytosis of MTB [189]. Complement receptors (CRs) expressed 
on the surface of macrophages recognize molecular complexes formed by 
complement and secreted bacterial proteins and shed cell wall components. 
Opsonized with C3b and iC3b components, MTB activates the alternative 
complement pathway and can be recognized by CR1 and CR3/CR4, respectively. The 
mechanism of generating opsonizing complement C3 peptides is specific for 
mycobacterial strains. A cell wall component of MTB can associate with complement 
fragment C2a to form a C3 convertase and produce opsonic C3b recognized by the 
CR3 receptor [198], [199]. One additional advantage of preferential CR-mediated 
MTB phagocytosis is the low level of superoxide inducted in alveolar macrophages 
during this process compared to MR dependent phagocytosis [200]. In a second 
mechanism of recognition, mannose receptors (MR) recognize mannose 
components of the most prevalent bacterial cell wall lipoarabinomannan (ManLAM). 
Although less prevalent than CR-mediated phagocytosis, MR recognition plays a 
crucial role in survival of MTB inside the host cell, since phagosomes created in this 
process have limited ability to fuse with lysosomes [201] 
DCs use the C-type lectin receptor DC-SIGN to recognize and take up mycobacteria. 
Similar to MRs, DC-SIGN binds the mannose cap of ManLAM and its progenitors like 
PIM. In activated DCs, ManLAM augments pro-inflammatory TNF, IL-12, IL-6 cytokine 
production and expression of the co-stimulatory molecules CD80 and CD86. PIM acts 
as an inhibitor of these effects and also inhibits DC maturation [202]. Although, 
when C-type lectin receptor genes were deleted, no significant change was noted in 
the progress of the infection. Nevertheless, when a component of downstream 
signaling cascades of DC-SIGN, CARD9, was deleted in mice, an excessive neutrophil 
influx into the lungs resulted in accelerated mortality [203]. 
1.3.3 Prevention of phagosome maturation. 
An important element of MTB pathogenesis is the ability to evade phagosome 
degradation inside infected macrophages or DCs. MTB prevents fusion of 
phagosomes with lysosomes by inhibiting the maturation. Understanding this 
process is essential for discovery of new drug targets as well as development of 
potential attenuated vaccine strains. Since the phagosome maturation process is 
linked to changes in the pH, it was initially proposed that the bacterial urease 
enzyme producing ammonia counteracts lowering of the pH inside the vesicles. 
Studies with urease-deficient strains have shown that these strains are still able to 
arrest phagosome maturation [204]. Recent studies suggest that the process of 
evading phagosome maturation is facilitated by inhibition of Rab7. Rab7 is a 
signaling molecule for phagocyte fusion with lysosomes. Additionally, markers of 
early phagosomal stage, like Rab5, and cell membrane proteins are retained in the 
membrane. This allows for nutrient and microelements acquisition which is essential 
for MTB metabolism and replication [205]. ManLam plays an important role in 
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inhibition of phagosome maturation. It disrupts the association between the Golgi 
apparatus and phagosomes harboring bacteria. In studies with latex beads coated 
with ManLam, phagosomes were unable to recruit SNARE protein syntaxin 6 
(responsible for spontaneous calcium independent fusion of vesicles) and to 
accumulate cathepsin D and lysosomal hydrolase [206]. ManLAM by itself does not 
fully inhibit phagosomal maturation. Other bacterial products may be required to 
comple the process, or that not all phagosomes in the infected cell are being 
affected [207]. Despite the ability of MTB to interfere with phagosome maturation 
to avoid degradation, bacteria-derived antigens are eventually presented to the 
adaptive immune system.  
Toll-like receptor 2 (TLR) is the main pattern-recognition receptor involved in the 
process of pro-inflammatory signaling during MTB infection. TLR2 recognizes over a 
hundred agonists produced by mycobacteria, including lipoproteins, mannams and 
lipomannans. Bacterial DNA can be recognized by TLR9, which leads to cytokine 
production by macrophages and DCs. Similar to DC-SIGN, deletion of TLR2 or TLR9 
does not lead to severe exacerbation of the disease. However, deletion of both 
receptors in mice leads to increased susceptibility to MTB infection [208]. Additional, 
deletion of downstream signaling molecule MyD88, shared by TLR2, 4 and 9 
receptors also leads to rapid mortality in MTB infected animals [209].  
Other pattern-recognition receptors are also involved in detecting MTB components. 
Nucleotide-binding oligomerization domain protein 2 (NOD2) recognizes 
peptidoglycan components of the mycobacterial wall and NOD-, LRR- and pyrin 
domain-containing 3 (NLRP3) can recognize secretory protein ESAT6 and the 
secretion system ESX-1 [210], [211].  
As with HIV, induction of the immune response at the site of infection can be a two-
edged sword. Influx of monocyte-derived macrophages and DCs into the lungs 
provides additional targets for infection for MTB [196], [212], [213]. For example, 
induction of a pro-inflammatory response by virulent MTB via NLRP3 leads to 
necrotic, rather than apoptotic, cell death. This results in release of bacteria and 
immediate infection of freshly recruited macrophages and other myeloid cells. 
Mycobacteria does not have its own mechanism of cell to cell transmission, 
therefore induction of cell death followed by acquisition of cell bound or unconfined 
bacteria allows for efficient MTB expansion and dissemination [214]. 
1.3.4 Modulation of antigen presentation  
MTB modulates the development of the adaptive immune response mostly by 
interfering with antigen presentation, thus postponing priming and proliferation of 
antigen specific T-cells. Animal models have shown that during the initial stage of 
MTB infection, the onset of the adaptive response is delayed by weeks compared to 
other bacterial diseases [215]. 
MTB antigens are mainly processed via three antigen presentation pathways: MHC I, 
MHC II and CD1. One mechanism which MTB utilizes to inhibit antigen presentation 
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to T-cells is reduction of MHC II cell surface levels on APCs. In a standard pathway, 
antigens are degraded to peptides in phagolysosomes and loaded on the MHC II 
complex, which, if stable, is transported to the cell surface. Otherwise it is degraded 
via the endosomal pathway [216]. Inhibition of phagolysosome formation impair 
MHC II presentation. This mechanism plays a major role in the early phase of cell 
infection [217]. Other MHC II inhibitory mechanisms are also responsible for 
interfering with MHC II complex synthesis. MTB can downregulate formation of 
functional peptide MHC complex by inhibiting expression of class II transactivator 
(CIITA) [218], [219].  
Bacteria appear to inhibit the IFN-γ-induced up-regulation of MHC II expression in 
infected APCs. The degree of inhibition is higher when viable bacteria are being used 
compared to heat-killed bacilli, indicating that the mechanism, at least partially, 
relies on metabolic activity by the bacteria [220].  
The ESAT6 protein is able to inhibit the expression of MHC Class II molecules 
(particularly upon IFN-γ activation) by downregulating the expression of CIITA 
independently of TLR2 signaling, whereas the 19-kDa lipoprotein inhibits induced 
class II presentation through a TLR2-dependent pathway [221], [222]. ManLAM 
signaling trough MR can also counteract IFNγ induced expression in vitro. Taking into 
account that mycobacteria shed significant quantities of ManLAM, which could be 
found in substantial amounts in circulation, this can have an effect on bystander, 
non-infected cells [223–225]. 
MHC I presentation has not been shown to be affected by MTB evasion mechanisms. 
Bacterial antigens are usually presented on MHC I in a process of cross-presentation 
but due to the fact that MTB can escape from the phagosome to the cytosol, some 
of the antigens are presented via classical MHC I pathway. ESAT6 and CFP10 
bacterial secretory proteins can also cause disruption in the phagosomal membrane 
and leak into the cytosol, where degraded, can be loaded onto the MHC I molecules 
[226]. 
Mycobacteria have a complex cell wall compared to many other pathogenic 
bacteria. The main component is a glycolipid layer consisting of mycolic acid, 
peptidoglycan, arabinoglycan and LAM, as well as variety of glycol and lipoproteins. 
Hence, in addition to presentation of peptide antigens on MHC molecules, 
presentation of lipid antigens by CD1 antigen presenting molecules to CD1-restricted 
T cells may play a role in developing protective MTB-specific adaptive immune 
responses during pulmonary TB [227–229]. 
Previous studies have shown that lipid antigen presentation can occur by the detour 
pathway characteristic for MHC class I cross-presentation. This new 'detour' 
pathway for presentation of antigens from bacteria contained in phagosomes, 
demonstrates the significance of infection-induced apoptosis in the activation of 
CD8 T-cells specific for glycolipids and lipoproteins. Therefore, the ability of MTB to 
block apoptosis can be considered an evasion mechanism in this context [230]. 
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Similarly to MHC II molecules, MTB can also inhibit expression of CD1 molecules in 
DCs in vitro [231]. After in vitro infection of monocytes, which were stimulated to 
differentiate into DCs, the cells failed to induce CD1 expression. This shows that the 
infection of monocytes can impair their differentiation in vitro [232], [233]. 
Natural killer T-cells (NKT) are also involved in recognition of lipid antigens 
presented on CD1d molecules. Destined to be one of the first lines of defense, 
activated NKT cells produce large amounts of IFNγ after T cell receptor recognition 
of antigens presented on CD1d molecules. It has been shown that the NKT cells 
stimulation with α-galactosylceramide, can lower their susceptibility to MTB 
infection [234], [235]. On the other hand, no downregulation of CD1d expression in 
infected cells was observed and adoptively transferred macrophages upregulate the 
cell surface expression of CD1d in MTB-infected lungs tissue [236]. Finally, mice 
which lack CD1d do not display augmented disease progression showing that CD1d-
restricted NKT cells are not absolutely required for control of MTB growth during the 
natural course of infection [237], [238]. 
1.3.5 Modulation of effector adaptive immune response 
During the initial stage of infection, or reactivation from the latent phase, multiple 
molecular and cellular innate immune events take place, but induction of adaptive 
immune response is severely delayed. From skin test studies using purified protein 
derivative (PPD), it is known that the T-cell response in humans require over 40 days 
to develop comparing to only a few in the case of other pulmonary bacterial 
diseases [239]. In mice, this period is shorter and does not exceed three weeks 
[234]. Interestingly, adoptive transfer of antigen specific CD4+ T-cells into infected 
animals does not have an effect on bacterial load in the lungs or overall survival of 
the mice [240–242]. Late development of T-cell responses can be attributed to 
delayed priming having its origin in inhibition of APC maturation. It has been shown 
that in resistant mice bacteria are disseminated earlier to the PLN than in 
susceptible strains allowing for earlier T-cell priming [240]. Another important factor 
is an exceptionally slow replication of MTB with the doubling time being 20-24h, 
compared to less than one hour in the case of other common bacterial pathogens 
[243]. The exact mechanism of the delayed DC migration to the draining lymph 
nodes is yet unknown. One of the proposed explanations is the inhibition of CC-
chemokine receptor-7 (CCR7) signaling by MTB. Also interleukin-10 was shown to 
contribute to this effect [244],[245].  
It is not defined which population of dendritic cells are responsible for the delivery 
of bacteria to the lymph nodes but it is clear that arrival of DCs infected with viable 
bacteria correlated with emergence of CD4+ MTB specific T-cells [240]. Since T-cell 
priming and proliferation coincides with dissemination of the disease to the LN it 
was suggested that this can affect migration of T-cell to the site of primary infection. 
It was shown that naive T cells upregulate CD44 and downregulate CD62L, and begin 
to accumulate in the lungs with similar kinetics as when T-cells were primed with 
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soluble protein antigens [246]. However, during the course of infection, 
development of regulatory T-cells is observed which contributes to delayed priming 
and migration of CD4+ T cells to the lungs. Importantly those T regulatory cells were 
shown to contain MTB antigen-specific cells [247]. On the other hand BCG 
vaccination also was shown to induce MTB specific Tregs therefore accumulation of 
these cells may not be the direct reason why the immune system is unable to clear 
MTB infection [248–250] 
The capacity of CD4+ T-cells to mediate protection is not fully understood. It has 
been demonstrated that production of IFNγ by CD4 cells is critical for the induction 
of bactericidal activity after phagocytosis by macrophages and IFNy knock-out 
animals succumb to the infection extremely rapidly [251]. Production of other pro-
inflammatory cytokines like TNF has also been shown to play an important role in 
controlling TB infection [252]. As mentioned before in chapter 1.2.6, effector CD4+ 
T-cell can produce more than one cytokine at a time and multi-functionality are 
associated with better protection against MTB infection [253], [254]. CD4+ and CD8 
T-cells producing several cytokines have been identified in newly BCG vaccinated 
children and in TB patients. Therefore, eliciting T cells able to produce several pro-
inflammatory cytokines simultaneously by new TB vaccine candidates is considered 
to be a major goal [254], [255]. 
It is very important to note that in the case of TB, most of the infected individuals 
either become latently infected for life, or are able to clear the infection without 
noticeable symptoms. Therefore, information gathered studying MTB-infected 
individuals comes mainly from the minority of infected patient that are unable to 
control the infection. This may skew our understanding of what is protective and 
what is disruptive in the anti-MTB immune response.  
1.3.6 Granuloma formation 
Granuloma formation is one component of the immune response against MTB that 
is constantly under debate. It is a characteristic feature of immune responses against 
pathogens that cannot be controlled and eradicated by the immune system. When 
phagocytic and cytotoxic cells are unable to kill the pathogen, other innate and 
adaptive immune cells accumulate around the infected cells. During MTB granuloma 
formation, undifferentiated monocytes congregate around infected macrophages 
and DCs. and after activation with IFNγ produced by CD4+ T-cells activation increase 
in size and cell organelles creating so called “foamy cells” [256]. IFNγ also acts on 
neighboring macrophages which fuse their cell membranes creating polynuclear 
cells (giant cells) [257], [258]. Membranes of the giant cells overlap with each other 
creating a multilayer, zipper barrier that restrains physical dissemination of the 
bacteria outside the granuloma center. The core of a granuloma is surrounded by T-
cells and B-cells, together with neutrophil and NK cells. Epithelial cells create a sack, 
which is further surrounding and reinforcing formation of the lesion. TNF-α is 
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believed to be a crucial cytokine maintaining the integrity of the granuloma 
structure [214], [252], [259], [260].  
Human granulomas are more organized than murine lesions and contain calcified 
aggregates of necrotic macrophages. Due to the dense structure, the center of 
granuloma is anaerobic and partially deprived of nutrients required for MTB 
replication. It is believed that by combining a growth-restricting environment 
surrounded by a tight cellular barrier, the host organism can control dissemination 
of the infection. Latently infected, asymptomatic individuals can control the 
infection indefinitely. However, due to the limitedations in probing methods the 
amount of bacteria being harbored in granulomas of infected patients is unknown 
[214], [261–263]. Although granulomas may play an important role in controlling the 
infection, it is possible that granuloma formation is part of a long-term survival 
strategy for the bacteria. Due to its structure, granulomas can become a niche for 
Figure 3.  Formation and maturation of lung tuberculous granulomas. Adapted from Silva 




dormant bacilli, with giant cells and foamy macrophages creating a barrier. Whilst 
the macrophage barrier may prevent dissemination of bacteria, it also prevents an 
influx of antigen specific T-cell into the granuloma, which could activate infected 
cells to kill phagocytosed bacteria [264], [265]. It is debated whether the TB 
granuloma is a host defensive mechanism, or a bacteria-induced survival feature. 
We should keep in mind that humans and other natural hosts co-evolved together 
with MTB for millions of years. Thus, granuloma formation may be beneficial for 
both organisms on a population level. In the majority of the 2 billion people infected 
with MTB, reactivation rarely (10%) happens and it is usually associated with 
immune deficiencies. Despite that, TB is one of the most prevalent bacterial 
diseases. The available knowledge on how granulomas develop in healthy and 
asymptomatic individuals, and what characterizes successful control of the infection, 
is still limited.  
In recent years evidence showing that TB granuloma is not a static construction and 
that not all bacilli inside it are in a dormant metabolic state [214]. Studies in 
resistant mice strains have demonstrated that, although CFU (colony forming unit) 
load in the lungs remains stable after 6 weeks a subpopulation of bacteria continues 
to replicate while other bacilli are being killed. Those two processes balance 
themselves out creating a state of bacterial load equilibrium [266]. Another study of 
whole bacterial genome sequencing in monkeys has shown that MTB steadily 
accumulates mutations during latency [267].  
On the other hand it seems that not all bacteria are fully metabolically active during 
active phase of infection. Monotherapy with isoniazid (INH) has been shown to be 
ineffective not only due to the development of resistance but also due to the fact 
that INH is not an active form of a drug. Hence, it needs to be activated by bacterial 
catalase-peroxidase (KatG) to its active form of isonicotinic acyl-NADH complex. 
Because only active bacteria can be eliminated by INH, dormant forms survive 
unaffected suggesting that bacteria develop isoniazid resistance. Nevertheless, long 
lasting monotherapy with INS in latently infected individuals leads to sterility which 
provides further evidence that bacteria previously described as dormant, actually 
switch between active and latent state [268], [269]. 
A new interesting model of dynamic latency and its environment-dependent 
reactivation has been proposed. In this model, the majority of the bacilli lay dormant 
in the granuloma and only a few are metabolically active. Those “scouts” are able to 
“sense” the attractiveness of environment. If oxygen and nutrient conditions in the 
granuloma improve as a result of loss of structural integrity, the scouts can induce 
reactivation of dormant bacilli by secreting resuscitation-promoting factors (Rpfs). 
This kind of bacterial communication is common in other species like Pseudomonas 
[270–272]. One of the indirect evidence supporting this concept is increased 
bacterial recovery form sputum of actively infected patients before administration 
of MTB antibiotic therapy [273]. 
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1.3.7 Humoral response during TB infection 
Humoral responses against MTB have been considered to play a minor role in 
controlling the infection. Nevertheless, the largest population of lymphocytes in the 
granulomas are B220+ cells [274]. The reason why the B220+ cells accumulate is not 
fully understood, but it has been shown that they can play a role in regulating 
immunity within the lesions [275]. Also B-cell deficient mice show alteration in 
granuloma formation. Although those mice are not more susceptible to infection 
with MTB via the aerosol route, they succumb faster to infection than WT mice after 
intravenous inoculation [276–278]. Hamasur et. al have shown that passive 
immunization with LAM specific F’ab fragments of Abs results in lowered bacterial 
burden after intravenous infection [279]. Consequently, the role and significance of 
humoral immunity during MTB infection may need to be reassessed.  
1.3.8 Animal models of tuberculosis 
1.3.8.1 Non murine rodents 
In contrast to HIV most mammals are naturally susceptible to TB. Thus, finding a 
suitable model of human MTB infection should theoretically not be as demanding as 
in the case of HIV. In very early studies of TB, guinea pigs quickly became an animal 
of choice and were widely used. The reasons for choosing guinea pigs by Koch and 
others were the close similarity of tubercles (granulomas) and progression of the 
disease to that observed in people [280]. Other similarities which make guinea pigs a 
favorable TB model of human disease are mature lymphomyeloid complex in new-
born animals and similarities in the physiology of the pulmonary tract, especially the 
response of the lungs to inflammatory stimuli. Importantly, unlike mice and rabbits, 
guinea pigs can transmit TB between themselves via aerosol [280], [281]. 
Unfortunately out of the 20 inbred strains of guinea pigs developed in the first half 
of the XX century, there are only two are commercially available (strain 2 and 13) 
[282].  
Another rodent model is the rabbit. Rabbits are quite susceptible to TB which causes 
excessive lung damage. Inbred strains with different level of susceptibility to TB 
were developed. TB resistant rabbits are excellent model for study of cavitary TB 
whereas in most susceptible strains disseminated, systemic disease is a 
characteristic trait. [283], [284], rabbits are usually not inbred anymore therefore 
their usefulness is limited.  
1.3.8.2 Non-human primates  
The use of primates in studies of TB has the same limitations as described for animal 
models of HIV infection. Similarly, in the case of TB, most studies are performed with 
the use of rhesus monkeys which are highly susceptible to TB and other virulent 
mycobacteria [285]. 
Bronchial infection results in a rapid progression of primary pulmonary TB followed 
by quick dissemination. When a low dose of inoculum is administered, only half of 
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the animals develop symptoms immediately, whereas the other half is considered 
latently infected (positive quantiferon assay and TST). Interestingly, latency 
described in those monkeys is not uniform. Animals that do not progress to active TB 
have significantly lower CFU and pathology score in the lungs. Additionally, some of 
the animals with low CFU revert spontaneously to an active form of TB, while some 
harbor intermediate levels of bacteria. Although non-symptomatic, these animals 
described as percolators, have significant levels of replicating MTB. In monkeys with 
active, TB extensive caseous necrosis along with liquefaction of the caseous have 
been shown to result in cavity formation, whereas in latent monkeys solid fibrotic 
and solid cellular granulomas are observed [286–289]. It is worth noticing that while 
it is not fully understood why certain monkeys develop active pulmonary TB and 
others do not, the animals are not inbred. However, the genetic variability is 
partially limited compared to wild animals.  
Similar results were obtained from Philippine cynomolgus monkeys which are 
considered more resistant to TB than rhesus macaques, although no cavity was 
observed [290]. In both species direct delivery of a small MTB inoculum into the 
lungs is critical in achieving human-like progress of the infection. Nevertheless, these 
animals are still more susceptible to TB than most humans.  
1.3.8.3 Mice 
Although other rodent models of TB infection seem to mimic human TB infection 
better, due to the many tools that are available, mice have been the model of choice 
in the majority of the studies. Two strains of inbred mice which are mainly used are 
C57BL/6 (B6) and BALB/c. The former is considered to be one of the most genetically 
resistant to TB while latter is highly susceptible to i.v. infection but has a relatively 
good resistance against aerosol infections [291]. These strains develop disease that 
could be described as an intermediate or chronic disease. After initial exponential 
growth of the bacteria for 5-7 weeks, replication is controlled and reaches plateau at 
~10
6
 CFU per lobe. This coincides with accumulation of antigen specific effector CD4+ 
and CD8+ T-cells and formation of granulomas. The number of bacteria is 
maintained at this level until the mice die one year or one year and a half later. The 
granulomas that form in MTB-infected B6 and BALB/c mice lack necrotic centers and 
the lesions do not show signs of hypoxia. Data indicate that innate and adaptive 
immune responses in these mice are sufficient to arrest the growth of MTB, but 
their ability to eliminate bacteria is limited [292–294]. 
Despite the large number of mouse strains available, they are not all being 
commonly used in TB research. The mouse model is criticized for lacking many of the 
features of human TB, but while this is true for B6 and BALB/c mice, in other strains 
some certain human-like characteristics are better represented. For example 
C3Heb/FeJ, one of the sub-strains of the well-characterized C3H strain, has been 
shown to develop highly organized necrotic lung granulomas after a low-dose 
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aerosol challenge with pathogenic MTB Erdman strain, and was shown to be more 
susceptible to infection that the parental strain [295], [296]. 
It was determined that the sst1 locus plays a key role in the development of 
pathogenesis of necrotizing lung granulomas. It has been shown that congenic mice 
on the B6 strain background which carry the sst1 locus derived from C3HeB/FeJ 
animals are more susceptible to TB than the parental B6 strain [297].  
It was shown that TB-caused cachexia is controlled by combinations of different 
alleles, therefore introducing more genetic diversity into the inbred strains can 
result in improved phenotypic models [298]. Latency is one of the most important 
features of human TB, which is still not properly represented by any of the murine 
models. A partially successful model, which is still being used, was developed in 
1950s at Cornell University. Resistant mice were infected with MTB and after the 
bacterial load reached a plateau, the animals were treated with isoniazid and 
pyrazinamide to kill replicating but not dormant bacteria. Approximately three 
months after cessation of the antibiotic treatment revival of active infection occurs 
in two thirds of animals [299]. This approach is laborious and although metabolically 
active bacteria are not detectable this model for some time, it only roughly 
resembles the physiology of latency, including the immune response and 
mechanisms of bacterial containment in latently infected humans [300], [301].  
Similarly to HIV infection, it will probably be impossible to model all features of the 
immune response toward TB in a single mouse model. Additionally, the choice of 
inbred strains that carry unique combinations of genetic variants, which are not 
typically representative of the whole species, can result in missing or omitting 
results.  
1.4 CO-INFECTION OF MTB AND HIV 
The most prominent symptom of HIV/TB co-infection is the reactivation of latent TB 
due to the development of AIDS in patients. In the classical model of reactivation, 
the slow decline in CD4+ T-cell mediated immunity against MTB triggers disruption 
of granulomas and bacterial replication is no longer controlled. In co-infected 
individuals, the CD4+ T-cell count decline is a leading factor in TB progression. 
Nevertheless other factors play an important role in driving progression of MTB- and 
HIV-mediated disease.  
1.4.1 Induction of active TB during co-infection 
Population studies have demonstrated that the chance of developing an active form 
of TB is estimated to be between 5-10% in a lifetime. However, this risk increases 
more than 10 fold in HIV positive individuals [302]. Additionally, in studies of mine 
workers in Malawi and South Africa it has been shown that HIV positive individuals 
were two to three times more likely to develop symptoms of active TB only two 
years after estimated HIV transmission. Due to the high prevalence of TB in this 
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community and working conditions favorable for aerosol infection transmission, 
these incidences were a mixture of reactivated and newly acquired TB. Clinical 
discrimination between re-infection and re-activation of MTB is very difficult. 
Nevertheless, because mechanisms of MTB re-infection and re-activation are not 
identical, grouping subjects with re-activated latent and acute infection together 
during studies can distort the relevancy of the findings. By restriction fragment 
length polymorphism typing of the MTB insert sequence 6110 (IS6110) it has been 
shown that in seropositive workers the chance of developing an active form of 
pulmonary TB resulting from a newly acquired infection was 2.2%-5.5% higher than 
in HIV negative individuals [303–306].  
1.4.2 Bacterial transmission during co-infection 
One of the main anatomical manifestations of active TB is severe lung tissue 
destruction and creation of cavities (cavitary TB). As described before, this form of 
TB is the most infectious and generates the highest concentration of bacilli in 
sputum samples [307]. It has been shown in numerous studies that aggravated 
immune responses contributes to tissue damage during development of active MTB, 
and it is speculated that MTB induces this inflammatory reaction to allow for 
transmission between hosts. In the lungs of co-infected individuals, the number of 
tubercle lesions as well as the frequency of MTB-induced cavities is lower than in 
patients infected with MTB alone. Additionally, the CD4+ T-cell count in blood of co-
infected individuals correlated with the probability of cavitary development. In 
patients with a CD4+ T-cell count below 200 per µl, the likelihood of cavitary TB was 
four times lower than in patients with a CD4+ T-cell count above 500 per µl [308].  
As a result, the number of bacteria in sputum samples of co-infected patients is 
lower. Whether this reflects on the infectivity of sputum from those patients has not 
been tested. Due to that fact that most TB diagnostics is still based on acid-fast 
staining, the lower CFU results in poor detection of MTB cases among seropositive 
individuals [89], [309].  
 These findings are unexpected since in the majority of other pulmonary pathogens 
like influenza virus or pneumococci, immune suppression is usually associated with 
an increased pathogen load in sputum or mucus as well as prolonged infection [310].  
1.4.3 Exhaustion in co-infection 
T-cell exhaustion is another mechanism that may help explain the failure of the host 
immune response and could be associated with increased speed in which latent TB 
develops in seropositive individuals. It is not clear weather the exhausted phenotype 
of HIV antigen-specific CD4+ T-cells can be observed for the MTB-specific T-cells in 
the lungs of co-infected individuals. As previously described, during HIV infection 
PD1 is considered a marker of immune exhaustion. PD1 and Tim3 can be expressed 
on cells that are unable to produce cytokines and proliferate upon antigen 
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stimulation. Strikingly, in mice deficient in PD1, MTB infection causes an excessive 
pro-inflammatory response in the lung tissue that leads to premature death of the 
animals. Following depletion of CD4+ T-cell in these mice partially attenuates the 
excessive inflammation [311]. Additionally, it has been shown that PD1 is expressed 
by functional MTB antigen-specific T-cells in the lungs of mice. CD4+ PD1+ T-cells 
isolated from MTB infected animals were able to proliferate and produce pro-
inflammatory cytokines in vitro [312]. On the other hand, it was shown that a high 
blood count of pro-inflammatory MTB-specific CD4+ T-cells that produce multiple 
cytokines correlates with a lower CFU in the lungs of MTB-infected individuals. In 
patients with pulmonary TB, the majority of the cells were able to produce only TNF 
and IFNγ. 6 months after antibiotic treatment and significant reduction of the CFU in 
the lungs, both the CD4+ and the CD8+ antigen-specific T-cells regained the ability to 
proliferate and produce multiple cytokines. [253]. This finding suggest that the 
exhaustion mechanism being responsible for the failure to control HIV infection does 
not need to be directly detrimental for the immune response against MTB, and that 
expression of inhibitory molecules in different locations play a different role in host 
immunity.  
1.4.4 Lungs as a harbor of HIV replication 
Two interesting observations have been made in studies of bronchoalveolar lavage 
(BAL) from MTB/HIV co-infected individuals. Samples collected from the area of the 
lung affected by MTB contained higher levels of HIV branched DNA (bDNA) and p24 
protein than samples collected from relatively unaffected tissue (localization was 
based on chest X-ray analysis). Additionally, the viral load in the lungs was higher 
than in plasma from the same patient that was not yet treated for TB. After 
antibiotic treatment, the virus load in the lungs decreased. Interestingly another 
correlation was made between elevated levels of TNF in the areas containing high 
number of granulomas and p24 levelsa [313]. Another study has confirmed the 
increased virus load in lungs compared to plasma. The median HIV concentration in 
lung pleural fluid was four times higher than in plasma. Again, increased expression 
of pro-inflammatory cytokines was detected which correlated with virus loads in the 
lungs. Interestingly, it was shown that in the lungs a substantial amount of the virus 
is replicating in CD14+ macrophages, whereas in blood the virus is almost exclusively 
lymphocyte-derived [314], [315]. These results show that the virus replicates 
preferentially at the site of MTB infection which can be a substantial virus reservoir.  
Interestingly in co-infected individuals had lower CD4+ T-cell levels than ones 
infected with only MTB. CD4+ T-cell levels were also lower in comparison to 
seropositive patients living in the same community but with no confirmed MTB 
infection [316]. This could be an inclination that virus replication in the co-infected 
lungs is not mainly lymphocyte dependent. On the other hand, it could be associated 
with the different structure of the lesions in co-infected patients. CD4+ cell T-cell 
depletion, resembling the one occurring in the gut could be the reason for observed 
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differences. Additionally, yield of broncholavache sampling may not be a good 
representation of cell arrangement in the lung tissue.  
In the perspective of animal models of co-infection it is worth noting that in 
cynomolgus macaques latently infected with TB and SIV there was no increase in 
peripheral virus replication described. Nevertheless, acute and transient decrease in 
the number of peripheral CD4+ T-cells correlated with time of TB reactivation [317].  
Lawn et al. showed that HIV propagates in macrophages from co-infected patients, 
which underlines the importance of these cells, together with monocytes and DCs, 
as common hosts for HIV and MTB replication [314]. Co-infecting the same cell is yet 
another dimension of how these two pathogens could interact with each other. It 
has been shown that in vitro infection of alveolar macrophages with MTB caused 
reduced induction of apoptosis in cells isolated from seropositive individuals 
comparing to healthy donors [300]. This was associated with elevated levels of IL-10 
rerelease. Direct co-infection of monocyte-derived macrophages in vitro has been 
shown to have a detrimental effect on the control of the replication of both HIV and 
MTB. Co-infection also resulted in a decreased viability of the cells. Increased levels 
of interleukin 1β, -6 and -8 (IL-1β, IL-6, IL-8) in co-infected cultures comparing to 
MTB infected ones indicates that co-infection can have a by-stander effect on other 
cells in a form of additional cytokine stimulation[318].  
It is worth noting that MTB/HIV co-infection of the same cell is probably a rare 
event. However, the micro-environment of the TB granuloma may increase the 
chances of it occurring. Additionally, the high number of potential target cells in the 
granuloma may enhance the effect of released cytokines, mycobacterial and HIV 
antigens. Additionally, as described before, HIV proteins can cause an exogenous 
effect on none infected cells. Macrophages infected with MTB released less TNF 
when purified Nef was added to the in vitro culture. This lead to decrease in 
bacterial killing and TNF-dependent apoptosis [319]. The effect of mycobacterial 
products on enhanced maturation and increased ability to mediate trans-infection 
by DCs have been described by us in study I. It will be described in more detail in the 
following section.  
1.4.5 Impact on the development of active TB before AIDS 
One intriguing question regarding HIV infection in MTB co-infected individuals, is the 
scale of modulation of immune response against MTB before the development of 
AIDS. Addressing this issue in clinical settings is particularly difficult due to the 
inability to determine the exact time of HIV transmission. Since the symptoms of the 
acute phase after virus infection are not specific enough, the only way to determine 
the time of infection is to monitor seroconversion of individuals at high risk. 
Geldmacher et al. tackled this problem by monitoring the HIV status of 114 healthy 
individuals that were considered to be latently infected with MTB. Latency was 
confirmed by a PPD skin test, an IFNγ release assay and restimulation of PBMC with 
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the MTB-derived ESAT-6 protein. In comparison to the HIV positive latently infected 
individuals, seronegative controls had higher levels of MTB-specific CD4+ T-cells in 
circulation. In four out of five individuals that seroconverted, acute infection with 
HIV resulted in immediate depletion of CD4+ T-cells. Importantly, those individuals 
did not show symptoms of TB reactivation and remained asymptomatic until the end 
of the study. Soon after HIV transmission, an active form of TB was diagnosed in 
patients where the CD4+ T-cell population did not decreased after seroconversion. 
Interestingly, this phenomenon was associated with TB but not with chronic CMV 
infection [320], [321]. Although these studies show a drastic impact of acute HIV 
infection on the systemic CD4+ T-cell response against MTB, it is yet to be 
determined to what extent this CD4+ T-cell depletion in peripheral blood translates 
to depletion of antigen specific cells at the site of the infection.  
1.4.6 Granuloma as a site of co-infection  
It has been shown that MTB/HIV co-infected patients have a similar number of 
tubercle lesions as in the patients latently infected with MTB alone. Interestingly, in 
the granulomas of co-infected patients the expression of three major pro-
inflammatory cytokines IFNγ, IL-12 and TNF was increased. Also TNF expression 
coincided with necrotic granulomas [322]. One needs to bear in mind that the 
increased expression of cytokine mRNA in the tubercles does not imply whether 
these cells are HIV or MTB-specific. A partially contradictory study was conducted 
with the use of cells isolated from BAL of seropositive BCG-vaccinated individuals. 
Cells re-stimulated with BCG antigens produced less IL-2, TNF and IFNγ in 
comparison to HIV negative individuals. These individuals were not infected with 
MTB, although BCG vaccination is in fact infection with an attenuated 
Mycobacterium bovis strain. The inability of the CD4+ T-cells to produce pro-
inflammatory cytokines does not prove that the same defect would occur in case of 
an infection with a pathogenic mycobacterial strain [316]. Another contradictory 
study has shown decreased levels of TNF production in lesions of co-infected 
individuals compared to MTB-infected controls. The granulomas displayed extensive 
necrosis, reduced TNF production and to be unorganized [323]. An important fact 
when comparing these two studies is the fact that the latter was performed as a 
retrospective necropsy. Lungs were obtained from AIDS patients who died between 
1995 and 2001, and their CD4+ T-cell count was not stated. Whether or not they had 
been treated with ART therapy is also unknown. Thus, they represent an end stage 
of the disease rather than reflect an immunological situation in the granulomas of 
latently co-infected patients. 
Not surprisingly, also IFNγ production has been shown to be decreased in AIDS 
patients with active pulmonary MTB compared to patients with latent TB [324]. It is 
worth noting that although low levels of IFNγ was detected after restimulation of 
PBMC with PPD antigen, the percentage of MTB-specific IFNγ-producing T-cells in 
BAL fluid was significantly higher in patients with AIDS [325]. These studies clearly 
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illustrate that the process of TB reactivation, due to HIV infection and progression of 
the disease is a dynamic, localized process. Hence, it is important to better 
understand how MTB and HIV influence host immunity in vivo at early and late 
stages of co-infection.  
1.4.7  Immune reconstitution inflammatory syndrome (IRIS) 
One of the unexpected results of the development of antiretroviral therapy was the 
development of IRIS in co-infected patients. TB is the underlying factor most of IRIS 
manifestations, but other bacteria like cocci, non-tuberculosis mycobacteria, or 
viruses like CMV, Herpes simplex or Hepatitis virus C also provoke the development 
of this condition. Restoration of the immune response to combat the infections 
results in a robust inflammatory response, which in other circumstances would be 
beneficial to the host but in severely immunosuppressed individuals results in life 
threatening symptoms. The main manifestations of IRIS are severe fewer, 
enlargement of lymph nodes and reactivation and dissemination of TB lesions which 
cause respiratory dysfunction, hepatomegaly and splenomegaly [326]. Diagnosis of 
IRIS is problematical and mainly based on clinical observations. The vast number of 
possible symptoms in co-infected patients makes diagnosis difficult even for 
experienced clinical staff and it can be an additional obstacle to ART treatment 
programs in high TB endemic countries [327]. Although IRIS depends on the 
restoration of a functional immune system, it is the individuals with the lowest CD4+ 
T-cell counts that are prone to developing the syndrome. For the majority of co-
infected patients, the risk of developing IRIS after initiation of ART varies between 
less than 10% to over 40% and the risk decreases over time. Due to the different 
pace in which individual patients react to ART and how fast the immune system 
recovers, IRIS can manifest itself even 3 months after the beginning of the treatment 
[326]. Even though the risks of IRIS, ART or HAART are recommended to be initiated 
in all AIDS patients with identified opportunistic infections not later than 3 weeks 
after the beginning of the antibiotic treatment [327].  
1.4.8 Co-infection after HAART and antibiotic treatment 
When MTB is the co-infecting pathogen of HIV+ patients, the majority of the 
detrimental immune responses are mediated by newly proliferated MTB antigen-
specific CD4+ T-cells producing IFNγ, IL-2 and IL-12 [328]. This leads to activation of 
macrophages and DCs in the granulomas, which induces reactivation and granuloma 
disruption [329]. There is limited knowledge on how the immune system responds 
to and controls MTB during long timeperiods after ART. One of the few studies 
addressing this question was conducted by Wilkinson et. al. PBMC from seropositive 
patients who were infected with MTB. The patients were treated with HAART, and 
antibiotics were regularly administered up to a year after the initiation of HAART 
therapy. Out of the MTB antigen specific CD4+ T-cells identified, central memory 
cells and terminal effector cells were the first cells to expand by week 12, followed 
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by appearance of greater numbers of naïve cells by week 36. Although the overall 
CD4+ T-cell counts increased steadily, the percentage of MTB antigen-specific T-cells 
declined within the total CD4+ T-cell population [330]. Although most of AIDS 
patients who are being diagnosed with and MTB are currently being treated for both 
infections, there is that they will be re-infected after successful antibiotic treatment. 
There is also a chance of patients who were not infected with MTB prior to ART 
therapy to become infected. Due to the fact that more and more patients in MTB 
endemic areas are being successfully treated with ART this issue needs to be 









The overall aim of this thesis was to investigate interaction between HIV and 
M.tuberculosis infection from the perspective of hosts immune system and 
modulation of which mechanisms of immune response directed against these two 
pathogens could be responsible for increased susceptibility to MTB and HIV during co-
infection.  
 
Specific aims of studies presented in this thesis were: 
 
• To develop murine MTB/HIV co-infection model in immunocompetent 
animals (Study IV) 
• To gain insight into role of immmunomodulatory cells in the natural 
differential susceptibility to M.tuberculosis (Study I) 
• To assess impact of chronic M.tuberculosis infection on immunogenicity of 
HIV vaccine (Study III) 
• To investigate effects of M.tuberculosis infection of macrophages on Ability 




3 RESULTS AND DISCUSSION 
 
3.1 STUDY I 
Failure to recruit anti-inflammatory CD103+ dendritic cells and a diminished CD4+ 
Foxp3+ regulatory T cell pool in mice that display excessive lung inflammation and 
increased susceptibility to Mycobacterium tuberculosis. 
3.1.1 The importance of controlling host immune responses during 
MTB infection 
While innate and adaptive immune effector functions are required for control of 
MTB growth, excessive immune activation can lead to tissue damage and loss of 
function. In this study, we established a low dose nose-only MTB aerosol infection 
model and took advantage of WT inbred mouse strains that are either resistant 
(C57BL/6 and BALB/c) or susceptible (DBA/2) to MTB infection, in order to increase 
our understanding of the inflammatory response during pulmonary TB [291], [331], 
[332]. Comparisons between different inbred WT mouse strains have identified 
numerous features of the host immune response that may help explain naturally 
occurring susceptibility [240], [291], [332–337].  
3.1.2 Recruitment of myeloid cells in resistant and susceptible mice  
We took advantage of wild-type (WT) mice that are either resistant (C57BL/6 and 
BALB/c) or susceptible (DBA/2) to MTB infection [291], [331], [332]. To mimic the 
natural route of infection, we established an aerosol infection protocol in which the 
mice could be infected with a low dose(20 to 200 CFU) of aerosolized bacteria 
directly into the lungs. As expected, nine weeks after the infection, the lungs of 
susceptible DBA/2 mice harbored the highest number of bacteria (>10
7
 CFU), and 
hematoxylin/eosin staining showed that these mice had larger lesions and more 
extensive loss of alveolar architecture than the resistant strains. Because excessive 
inflammation in the lungs of susceptible mice seems to play a critical role in 
increased mortality, we investigated the cellular infiltrate in the lungs and in the 
pulmonary lymph nodes (PLN) draining the lung tissue. As expected, the total 
number of cells in the lungs and PLN increased dramatically after MTB infection in all 
mouse strains tested. Already three weeks post infection there was a significant 
difference in the total number of cells in the lungs of BALB/c mice compared to 
C57BL/6 and DBA/2 mice. We characterized influx of myeloid cells at various time 
points after MTB infection by examining expression of the cell surface markers 
CD11b, CD11c, Ly6C and Ly6G. Despite the differences in total lung cell numbers, the 
number of recruited Ly6C+ inflammatory monocytes was comparable between 
resistant and susceptible mice. Neutrophils were recruited in comparable numbers 
to the lungs of susceptible DBA/2 and resistant BALB/c mice, but because of the 
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lower number of total lung cells in infected DBA/2 mice, neutrophils accounted for a 
larger percentage of all cells. In resistant C57BL/6 mice numbers of neutrophils 
remained relatively low during the course of the infection.  
Inflammatory monocytes recruited into MTB-infected lungs rapidly upregulate 
CD11c [213]. Therefore, we enumerated the CD11b+CD11c+ cell subset, which 
contain dendritic cells and macrophages, in infected resistant and susceptible mice 
and determined the number of iNOS-producing cells within this subset. The number 
of both CD11b+CD11c+ cells and iNOS+ macrophages increased during the first six to 
nine weeks post infection before it reached a plateau. We did not detect a 
significant difference between the three mouse strains tested. 
 
Because myeloid cells are recruited early after MTB aerosol infection, a defect in the 
ability to recruit these cells may help exaplin susceptibility to MTB infection. In this 
study, we have shown that the increased susceptibility of DBA/2 mice is not caused 
by defective inflammatory monocyte-, neutrophil- or CD11b+CD11c+ DC- and 
macrophage recruitment to the infected lungs. We also showed that macrophage 
activation in the lungs is not different in resistant and susceptible mice. 
Figure 5. Bacterial burden and myeloid cell recruitment into the lungs of MTB infected mice.  
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3.1.3 A diminished population of CD103+ dendritic cells (αE-DC) in 
susceptible mice 
We also analyzed the myeloid CD11b-CD11c+ cell compartment, focusing on αE-DC 
in infected lungs and PLN. These cells have been shown to preferentially acquire and 
cross-present antigens acquired from apoptotic bodies to CD4 cell in draining lymph 
nodes and to have regulatory properties in the gut mucosa [338–343]. In this study, 
we showed that the number of αE-DCs increased dramatically in response to MTB 
infection in resistant, but not in susceptible mice. We found that the number of lung 
αE-DCs was approximately six-fold higher in C57BL/6 and BALB/c mice compared to 
DBA/2 mice 12 weeks post infection. The difference between mice and BALB/c mice, 
and the difference between BALB/c mice and DBA/2 mice, was not statistically 
significant. Nevertheless a higher number of αE-DCs were present in the more 
resistant BALB/c mice than in the DBA/2 mice. The reduced number of αE-DCs in the 
draining PLN may reflect reduced αE-DC migration from the MTB-infected lungs in 
susceptible mice.  
It has previously been shown that αE-DCs are derived from Ly6C+ monocytes [344]. 
We have shown that the influx of inflammatory monocytes is not defective in 
infected DBA/2 lung tissue, which suggests that monocyte differentiation into αE-DC 
is altered in the susceptible animals. Additionally, while the number of αE-DCs was 
reduced in infected susceptible mice, the number of CD11b+CD11c+ cells, which 
consist of mixture of monocyte-derived DCs and iNOS-producing macrophages, was 
not [213], [331], [345].  
 
To start delineating the role of αE-DC in host immunity during pulmonary TB, we 
investigated cytokine αE-DC production after MTB infection and compared it to the 
cytokine profile of other myeloid cells [338], [339], [341], [343]. Total lung cells were 
divided into four populations: The CD11b− CD11c+ populacon, which was further 
divided into αE-DCs and CD103− cells, which may contain alveolar macrophages; 
CD11b+CD11c+ cells (activated macrophages and DCs); and CD11b+CD11c− cells 
(inflammatory monocytes and granulocytes) [212], [213]. After stimulation with an 
MTB cell-wall extract, or with LPS, a high percentage of alveolar macrophages, 
 
Figure 6. Number of αE-DC recruited to the lungs and to the PLN after MTB infection  
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inflammatory monocytes/granulocytes and DC/macrophages produced TNF. In 
contrast, αE-DCs remained essentially TNF negative, but contined the highest 
percentage of TGFβ producers. this cytokine profile was observed in the early phase 
of infection (week 3 post infection) and in the chronic stage (week 12 post infection). 
Absolute number of TGFβ αE-DCs producing cells in susceptible mice were lower 
comparing to other strains. This clearly showed that comparing to other types of 
myeloid cells, αE-DCs have anti-inflammatory profile. 
3.1.4 A diminished CD4+Foxp3+ regulatory (Treg) cell population in 
MTB-infected lungs of susceptible mice 
The increased susceptibility and inflammatory response observed in DBA/2 mice 
caused by MTB infection correlated with a reduced lung αE-DC population. Because 
αE-DC in the gtu mucosa play a role in Treg cell induction, we wanted to determine if 
the susceptible mice also had a defective Treg cell response in the MTB infected 
lungs. Since the Foxp3 marker is unique to Treg cells, we enumerated the number of 
Foxp3-expressing CD4+ in the lungs and in the PLN of infected mice.  
It is worth noting that Foxp3 mRNA levels were the same in uninfected lungs of 
naïve C57BL/6 and DBA/2 [346] as well as Treg cells number in lungs of both strains 
(data not shown). 
We have found that CD4+ T cell population in the lungs of C57BL/6 and BALB/c mice 
contained a significant proportion of Treg cells that increased as the infection 
progressed. We made similar observations in the PLN, where the absolute number 
Figure 7.   Recruitment of Treg cells (Foxp3+ T-cells) into the lungs and PLNs and ability of 
these cells to produce IFNγ 
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of Treg cells increased significantly by week 12 post infection compared to week 3 
post infection. Importantly, the frequency and absolute number of Treg cells in the 
lungs of DBA/2 mice were dramatically reduced early after MTB infection as well as 
during chronic TB. In contrast, in the PLN the frequency and absolute numbers of 
Treg cells were comparable to resistant C57BL/6 and BALB/c mice, showing that 
MTB can have an organ-specific effect on Treg cells. 
In previous studies it has been shown that a reduction in Treg cell numbers in T. 
gondii-infected mice was preceeded by the induction of IFNγ in the Treg cells [347]. 
Therefore we investigated the functional potential of Treg cells in response to MTB 
infection.  
Total lung and PLN cells isolated from MTB infected C57BL/6 and DBA/2 mice were 
polyclonally re-stimulated in vitro. In the lungs and in the PLN of naïve and 
chronically infected animals, we found a similar percentage of IFNγ-producing CD4+ 
cells in both strains. After infection, a large fraction of Foxp3+ and Foxp3- CD4+ T-
cells produced IFNγ in lungs and PLN. At weeks 6 and 10 p.i we observed a 
significantly higher number of Treg cells producing IFNγ in the lungs of C57BL/6 in 
comparison to DBA/2 mice. In PLN the absolute number of IFNγ+ Treg cells was 
significantly higher only at week 6 p.i.. Among CD4+ Foxp3− T cells, we did not 
observe any significant differences in the PLNs but we did find a significantly higher 
number of IFNγ producers in the lungs of C57BL/6 mice at week 6 p.i.  
In summary, the reduced number of TGFβ-producing αE-DCs in lungs of MTB-
susceptible mice correlated with a diminished pool of Treg cells during the peak of 
the immune response (week 3 post infection) as well as during the chronic phase of 
the disease. Additionally, Treg cells in resistant and susceptible animals acquire the 
ability to produce IFNγ in response to infection with a clinical MTB isolate (Harlingen 
strain).  
3.1.5 Discussion 
In majority of pulmonary diseases, like the ones caused by pneumococcus or 
influenza infections, the immune response is able to clear the infection while not 
causing excessive damage to the lung tissue. In the case of pulmonary TB, excessive 
immune activation in untreated patients can lead to tissue damage in the lungs and 
loss of the physiological function. Hence, a balance between inflammatory and 
tolerogenic immune reactions must be maintained to control the infection and 
maintain organ function. The significance of controlling the inflammation caused by 
MTB is illustrated by the extensive lymphocyte- and myeloid cell infiltration into the 
lungs of Foxp3-deficient mice that lack Treg cells [348]. Here, we showed that the 
numbers of lung Treg cells with anti-inflammatory effector functions are significantly 
reduced during MTB infection of susceptible mice. By comparing animals displaying 
different level of susceptibility against MTB, we may model differences in MTB-
resistance in humans.  
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Recent studies using the mouse model have shown that Treg cells are able to inhibit 
the antigen-specific T cell response during pulmonary TB and reduce the ability of 
the immune system to control bacterial growth [247], [349], [350]. Also, in TB 
patients, the number of Treg cells increases in infected tissues which when isolated 
are able to suppress antigen-specific T cell responses in vitro [351].  
Studies performed in mice do not present a clear picture of the role of Treg cells 
duirng the course of the infection. It has been shown that Treg cell depletion 
reduces bacterial growth early after MTB infection [350], but not when Treg cells 
were depleted in later stages of the disease [352]. Depletion of regulatory cells was 
also associated with increased frequency of IFNγ- and IL-2-producing cells, but it had 
no effect on bacterial growth or lung lesions early after infection [248]. Adoptive 
transfer of Treg cells to infected animals resulted in increased T cell responses and 
slowed bacterial growth although this effect was temporary [247]. 
While Treg cells are associated with production of anti-inflammatory cytokines, our 
data show that during MTB infection, Treg cells are able to induce IFNγ production. 
This findings suggest a change in functional potential of the Treg cells during disease 
progression. 
In light of previous findings, we expected to observe an increased percentage of 
Treg cells in infected susceptible lung tissue. Instead, we found that the frequency of 
Treg cells was significantly reduced three weeks post infection, and that they were 
almost completely absent in chronically infected susceptible mice. Despite the 
differences in the infected lungs, the frequency of Treg cells in the PLN was similar in 
susceptible and resistant animals. Therefore, the lack of Treg cells in the chronically 
infected DBA/2 lungs was not due to systemic failure to generate this T cell subset. 
One of the reasons why Treg cells are not being recruited into the lungs could be low 
number or αE-DCs which were shown to be able to produce CCL22 chemokine 
(although under steady-state conditions and during allergic airway inflammation) 
[340]. The CCL22 receptor, CCR4, is expressed on Treg cells and induces Treg cell 
migration [353]. Moreover, a large fraction of lung αE-DCs are TGFβ+ during TB (Fig. 
5), and TGFβ is important for peripheral Treg cell function and homeostasis (43). 
Therefore, the inability of susceptible mice to induce αE-DC differentiation may help 
exaplin the low number of Treg cells. Overall, our results suggest that addressing 
regulatory role of αE-DCs and Treg cells at different stages of MTB infection may 





























Mice susceptible to tuberculosis versus resistant mice have:  
• higher bacterial burden in lungs and worse lung lesions  
• significantly reduced numbers of αE-DCs lung in lungs after MTB but not 
other myeloid cell subsets 
 
• lung αE-DCs have an anti-inflammatory cytokine profile  
• diminished pool of Treg cells in the lungs, but not in the draining 
pulmonary lymph nodes 
• MTB infection changes the functional potential of CD4+ Foxp3+ regulatory 
T (Treg) cells, which induce gamma interferon (IFN-γ)  
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3.2 STUDY II 
Mycobacteria-infected bystander macrophages trigger maturation of dendritic cells 
and enhance their ability to mediate HIV transinfection. 
 
3.2.1 Induction of cytokine production in DC by MTB-infected 
macrophages  
With the aim to mimic bystander effects mediated by an ongoing mycobacteria 
infection, and to investigate the cross-talk between DCs and mycobacteria-infected 
macrophages, we devised an in vitro model system comprised of human monocyte-
derived DCs and monocyte-derived macrophages. To asses the impact of different 
mycobacterial strains on macrophages, we infected them with BCG, MTB strain 
Harlingen or the highly pathogenic S96–129 isolate. Infected cells were either in 
direct contact with DCs, or isolated by a permeable membrane (0.2 µm) in order to 
assess the contribution of soluble mediators on macrophage function. DCs in direct 
contact with non-infected macrophages did produce cytokines. We found that 
exposure of DCs to soluble factors released by infected macrophages resulted in 
increased production of TNF, IL-12p40 and IL-6 in the cultures. When the cells were 
in direct contact with macrophages, cytokine production was two- to fivefold higher 
and seemed augmented depending on the mycobacterial strain used. To determine 
which cells were the main sources of the produced cytokines, we used fixed 
mycobacteria-infected macrophages. We observed that DCs were the main source 
of IL-12p40, whereas macrophages were main producers of TNF in the co-cultures. 
Regardless of whether the macrophages were live or fixed, different levels of 
Figure 8. Experimental setup of experiment measuring bystander impact of MTB infection of 
macrophages on DCs ability to mature and facilitate HIV transinfection. 
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cytokines were produced depending on mycobacterial strain. Taken together, these 
observations suggest that mycobacteria-infected macrophages stimulate DCs to 
produce pro-inflammatory cytokines after direct cell-to-cell contact as well as in 
bystander manner.  
3.2.2 Soluble factors released by mycobacteria-infected macrophages 
cause partial maturation of DCs 
To determine the effects of soluble factors on maturation of DCs, we assessed 
upregulation of CD86 and MHC class II. In comparison to LPS stimulation, which was 
considered 100% stimuli, upregulation of CD86 and MHC class II was higher in DCs 
that were co-cultured with infected macrophages without direct cell-to-cell contact. 
The effects of soluble factors were mycobacterial strain-dependent. With an 
exception for macrophages infected with the MTB S96–129 isolate, no changes in 
expression of the MR and DC-SIGN were observed. In contrast, full maturation of 
DCs and downregulation of the MR and DC-SIGN were observed when the cells were 
co-cultured with infected macrophages in direct contact. Interestingly BCG-infected 
macrophages induced less profound DC maturation as compared to infection with 
virulent MTB strains. In summary, we showed that DCs undergo partial maturation 
when exposed to soluble factors from infected macrophages, whereas direct contact 
between these cells leads to full DC maturation. 
3.2.3 DCs exposed to MTB-infected bystander macrophages display 
enhanced ability to mediate HIV trans-infection 
Maturation of DCs has been shown to affect their ability to mediate trans-infection 
of HIV to T-cells. Therefore, we asked whether DCs can still facilitate trans-infection 
under the influence of MTB infected macrophages. We pulsed DCs recovered from 
the co-cultures (both direct and membrane-separated) with HIV, washed and 
incubated the cells with activated PBMCs or CD4+ T-cells as target cells for the virus. 
Viral replication in CD4+ cells was assessed by quantification of p24 antigen in the 
culture supernatants. 
The DCs exposed to soluble factors in indirect cultures did not have enhanced ability 
to mediate HIV trans-infection of PBMCs, except when macrophages were exposed 
to the MTB isolate S96–129. Nevertheless, when immature DCs were exposed to 
supernatants from infected macrophage cultures their trans-infection ability was 
significantly enhanced as compared to supernatants from non-infected 
macrophages. Taken together, these findings suggest that DCs exposed to Mtb-
infected macrophages in bystander manner display augmented ability to capture HIV 




It has been previously shown that under non-inflammatory conditions, DCs 
precursors are recruited to the lungs and to the draining lymph nodes, and show 
rapid turnover [354]. As described in the introduction and discussion to paper I, 
when exposed to antigens during MTB infection, DCs migrate to the PLN and are 
responsible for T-cell priming. With the onset of an infection, this process changes 
dramatically. During the early phase of infection, DCs accumulate in the PLN [355]. 
Phagocytosis of antigens and direct interaction with other cells is the main 
stimulating factor for DC. We have demonstrated that DCs can be affected by 
components released from infected macrophages indirectly. In addition DCs 
exposed to these factors undergo partial maturation, including upregulation of co-
stimulatory molecules and MHC class II, and downregulation of the MR, while DC-
SIGN expression is sustained. Maturation of DCs is accompanied by increased 
production of the pro-inflammatory cytokine IL-12. Similar observations were made 
by Giacomini et al. who found that DCs and macrophages responded to MTB 
infection with distinct cytokine profiles, suggesting different and complementary 
functions of these two cell populations during the course of MTB infection [356]. 
TNF is one of the identified soluble factors released by MTB infected macrophages, 
which affects DCs. TNF has previously been shown to induce DCs maturation [357], 
[358].  
We showed that the strength of the maturation signals mediated by soluble factors 
are less efficient than the signals received via direct interaction with infected cells. In 
direct contact, maturation of DCs was on the same level as when stimulated with 
LPS which is in agreement with previous findings by other investigators [359]. 
Interestingly, the observed effects are related to the virulence of the mycobacterial 
strains that were used to infect the macrophages.  
LAM is one of the soluble factors released by infected macrophages, which could 
enhance DC maturation. In a recent study, we have shown that LAM facilitates DCs 
maturation as measured by CD80, CD86 and MCHII up regulation. ManLAM also 
induced production of IL-12 by DC, which could be blocked by LAM specific 
monoclonal antibodies. In the current study we show only partial maturation of DCs 
in comparison to the exposure of DCs directly to the LAM [202]. It is worth noting 
that concentration of LAM released by infected macrophages in culture was lower 
than one used with direct application of purified LAM. Additionally, LAM is usually 
accompanied by phosphatidylinositol mannoside PIM, which we show has an 
inhibitory effect on the DCs maturation. In the light of our new findings, partial 
maturation of DCs is not only the result of cytokines release by infected 
macrophages, but also products shedded from the bacterial cell wall which can play 
a role in DC differentiation [202]. On the other hand, binding of HIV by DC-SIGN can 
be blocked by a high concentration of mannan. Although the highest concentration 
of mycobacteria-derived compounds is expected to be found at sites with the 
highest bacterial burden, their presence is not limited to the lungs and the PLN. For 
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example, ManLAM can be detected in blood and urine [360], [361]. Also 
mycobacterial proteins can be found in sera of TB patients [362]. Quantities of LAM 
in sera and urine are high enough to be used in the development of diagnostic tools 
for TB [363]. This suggests that mycobacterial components can induce bystander 
effects in organs and tissues distant from the lungs.  
DC maturation has been demonstrated to enhance the ability of DCs to transfer HIV 
to T cells [364]. As described in the introduction section, ability of DCs to mediate 
trans–infection of HIV virus is dependent on DC-SIGN receptor. Because some of the 
components of mycobacterial wall can bind DC-SIGN and inhibits its function we 
investigated possible effects of soluble factors on ability of DC-sign to mediate trans-
infection. It has been shown that indirect activation of DCs by inflammatory 
mediators resulted in partial DC activation as compared to DCs matured by direct 
exposure to pathogens [365]. We have shown that partial maturation increased the 
ability to mediate HIV trans-infection to T cells, as compared with immature DCs.  
Studies have shown that upregulation of MHC II and co-stimulatory molecules on 
the surface of DCs enables close contact between DCs and T cells during formation 
of the immunological synapse, which enables DC to pass on the engulfed DC-SIGN-
bound HIV virus to CD4+ T cells [18], [366], [367]. Therefore it could contribute to 
virus spread from DCs to T cells. The importance of trans-infection was 
demonstrated in studies showing that HIV variants evolving during chronic infection 
conserve the ability to utilize DC-SIGN for efficient spread to CD4+ T cells [368].  
Conceivably, our findings suggest that mycobacterial infection alters immunological 
homeostasis and could affect cells in distant tissues. However, further studies are 
necessary to explore the complex interactions between DCs and other cell types that 
take place during MTB/HIV co-infection in order to uderstand the mechanisms that 





DCs exposed to soluble factors from MTB infected macrophages: 
 
• produce substantial amounts of IL-12 but not TNF 
• mature partially by upregulating CD86 and MHC II 
• can facilitate higher levels of HIV trans-infection via DC-SIGN 
receptor 
•  direct contact with infected macrophages is a stronger maturation 




3.3 STUDY III 
Mycobacterium tuberculosis Infection Interferes with HIV Vaccination in Mice. 
One of the neglected issues in the development of HIV vaccines is the fact that areas 
of the highest prevalence of HIV overlap geographically with MTB endemic regions. 
This will result in administration of prospective HIV vaccines to a population 
harboring latent as well as undiagnosed active TB. Other pathogens as well as 
physical fitness factors, such as age or malnutrition, have been shown to interfere 
with unrelated vaccinations. Hence, we decided to investigate the impact of chronic 
MTB infection on the efficacy of one of new HIV vaccine candidates [369–375].  
We chose the most immunogenic variant of the new MultiHIV DNA vaccine 
candidate delivered in an efficient DNA prime and double protein boost 
immunization regimen [184]. The vaccine was administered both intranasaly (i.n.) 
and intramuscularly (i.m.) to animals which had previously been infected with a low 
dose of aerosolized MTB (Harlingen strain) or to uninfected controls. It is important 
to note that C57BL/6 mice are considered resistant to aerosol MTB infection in 
comparison to other strains (as shown in study I). Animals were vaccinated 7 weeks 
after aerosol infection, which is 3-4 weeks after the bacterial burden in the lungs 




We tested both the cellular and the humoral immunogenicity of the vaccine 
candidate, including the ability to induce antigen-specific humoral responses in the 
vaginal mucosal surface, which is the main entry site for the virus during sexual 
transmission [376].  
3.3.1 MTB-infection impairs humoral responses induced by HIV 
vaccination 
Vaccination via the i.n. route resulted in moderate HIV-specific vaginal IgA levels 
four weeks later. In comparison, i.m. vaccination induced minimal levels of HIV-
specific IgA. After i.n. vaccination of MTB-infected mice, IgA titers in vaginal 
secretions were not reduced compared to uninfected controls. However, we 
observed a significant reduction in serum IgA levels. I.m. vaccination elicited high 
levels of IgA in serum of both MTB-infected and in uninfected animals. Even though 
Figure 9. Infection, vaccination and sample collection schedule 
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i.m. vaccination elicited high levels of IgA in serum, HIV-specific antibodies were not 
detectable in vaginal mucosa.  
To assess HIV-specific IgG production we collected blood samples from mice two and 
four weeks after the second protein boost was administered. In mice vaccinated 
i.m., we detected high levels of HIV-specific IgGs at both time points, irrespective of 
previous MTB infection. After vaccination via the nasal route and two weeks after 
the last protein boost, uninfected mice had high levels of IgGs, whereas MTB-
infected animals induced significantly lower antibody levels. Unexpectedly, IgG titers 
in i.n. vaccinated mice were diminished over two-fold two weeks later.  
Neutralization of viral particles is essential for quality assessment of induced 
humoral responses. Serum collected from both uninfected and MTB-infected 
animals, vaccinated i.n. at week 4 post infection and had the same neutralization 
capability. Serum from healthy mice vaccinated i.m. was characterized by high 
neutralization activity, whereas the serum collected from i.m. vaccinated MTB-
infected animals was significantly inferior in neutralizing the virus.  
Figure 10. Quantity and quality assessment of humoral responses toward the vaccine  
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In order to investigate in more detail the degenerative impact of MTB-infection on 
the neutralization capability of serum, we characterized the IgG1 versus IgG2a 
profile of HIV-specific IgG antibodies. We observed, that in healthy animals a 
significantly higher portion of HIV-specific antibodies were of the IgG1 type, whereas 
the IgG1 to IgG2 ratio in MTB-infected mice was significantly lower regardless of 
vaccination route.   
Overall, our results showed that MTB infection strongly affects the development of 
humoral immunity towards vaccine components, including mucosal IgA secretions, 
IgG levels, neutralizing capability and the IgG1/IgG2a-profile. These effects vary 
depending on the route of vaccination.  
3.3.2 MTB infection impairs cellular responses induced by the HIV 
vaccination 
HIV-specific multifunctional T cells that simultaneously produce more than one pro-
inflammatory cytokines (IFNγ, IL-2, or TNF) were recently suggested to play an 
important role in the control of HIV infection. Therefore, new HIV-vaccine 
candidates aim at eliciting these type of T-cell responses [171], [377]. We assessed 
the ability of the MultiHIV vaccine to induce Th1 responses in CD4+ and CD8+ T-cells 
following antigen stimulation of spleen cells in vitro and measuring the cytokine 
profile by flow cytometry.  
When the cells were grouped as IFNγ-, IL-2- or TNF monoproducers we observed 
that the number of IFNγ-producing MultiHIV-specific CD4+ T-cells cells was 
significantly reduced in animals that were MTB-infected, A similar trend was seen for 
TNF production, but no statistical significance was observed. In CD8+ T-cells 
compartment significant differences were noted between MTB infected and 
vaccinated-only animals in amount of IFNγ producing cells after i.n. vaccination .  
We also found that mice that were infected with MTB and vaccinated i.m. had a 
significantly lower amount of CD4+ T-cells producing all three cytokines 
simultaneously, as well as fewer CD4+ T-cells that produced IFNγ together with TNF, 
Figure 11. Quantity and quality assessment of polifunctional cellular responses toward vaccine  
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or with IL-2. No significant differences were observed between the i.n. vaccinated 
groups.  
In conclusion, our data show that MTB negatively influences induction of IFNγ-
producing CD4+ and CD8+ T-cells, as well as diminishes multiple effector functions 
elicited by i.m. vaccination believed to be vital for efficient control of HIV infection 
[377], [378].  
3.3.3 Discussion 
Studies of long-term non-progressors and elite controllers have identified certain 
characteristics of host immune responses that can successfully control virus 
replication and prevent AIDS development:  
- high number of multifunctional T cells that produce multiple cytokines in 
response to HIV antigens 
- early development of broadly virus-neutralizing antibodies  
- strong immune responses associated with genital mucosal surfaces to 
prevent, or lower, the transmission rate [376], [377], [379–383].  
Currently, most of the new vaccine candidates are screened against these 
requirements [384]. Although all recent vaccine candidates have shown protection 
in animal studies, and some of them induced protection in small groups of healthy 
volunteers during early clinical trials, they have failed in large-scale studies. Although 
we do not know exactly why substantial levels of protection has not yet been 
achieved, one of the important details worth noting is that large-scale trials are 
usually located in high MTB endemic countries [164], [165], [385]. Additionally, if an 
effective vaccine will be developed, due to co-localization of HIV and MTB in high 
epidemic regions, the HIV vaccine will be administered to a population in which MTB 
infection is frequent or sometimes omnipresent [8]. Although other pathogens have 
been shown to disturb the induction of immunity against vaccine components, MTB 
poses one particular clinical problem. In the majority of other pathogens, the 
infection time-span is short and infections are symptomatic. During TB, most latently 
infected individuals will never be clinically diagnosed due to the lack of symptoms 
and the fact that MTB can persist in a host throughout life [369–375]. Therefore, we 
chose to assess the efficacy of the vaccine in mice which develop chronic MTB 
infection and are able to control the bacterial burden in the lungs for over a 
year[294].  
In this study we found that chronic MTB infection impairs both humoral and cellular 
immune responses directed towards an HIV vaccine. Hence, we suspect that more 
than one mechanism is involved and we suspect that the inhibitory effect of MTB 
infection would be transient for other DNA vaccines. Previous studies indicate that 
MTB-induced specific Treg cells could contribute to the inhibition of the immune 
response toward the vaccine. Speculatively, these cells may suppress unrelated 
immune responses in a non-antigen specific manner [386–388]. As shown in Study I, 
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Treg cells are present in substantial quantities in the lungs and in PLN of MTB-
infected C57BL/6 mice at the time when the vaccine was administered [389]. 
Additionally, the impairment of humoral and T cell responses to intranasal 
vaccination could result from competitive antigen presentation in the respiratory 
tract associated lymph nodes [390–393]. Induction of Treg cells in the lungs and in 
the PLNs by MTB or co-localization of antigen presentation could help explain the 
inhibition of vaccine immunogenicity after i.n. delivery. However, due to the fact 
that immunogenicity of i.m. delivered vaccine was also diminished, is unlikely that 
there is only one mechanism causing this phenomenon.  
It has been shown in studies of helminthes, that protozoa infection induces Th2 
polarized responses during co-infection with malaria [394] . MTB is inducing a Th1 
type of response and although it may be beneficial in the first phase of vaccination 
this could have and unwanted effect on the evolution of humoral response [395]. 
Studies of HIV-positive subjects have shown that antibody class-switching is 
associated with the ability to neutralize, rather than only opsonize, the virus in a 
chronic phase of the disease. Development of neutralizing antibodies is associated 
with class switch and a change from a Th1 to a Th2 type of cellular response. Thus, it 
could be hypothesized that MTB in our model mainly drives production of 
opsonizing IgG antibodies and thereby inhibiting the development of more specific 
neutralizing antibodies [395], [396]. Stopping class switch from IgG1 to IgG2a in MTB 
infected animals could be the reason why, despite high levels of IgG in serum, 
animals infected with MTB prior to the vaccination had much lower neutralizing 
ability than healthy counterparts.  
In summary, we report for the first time, that chronic MTB-infection of mice prior to 
inoculation with an experimental HIV vaccine has a detrimental effect on vaccine-
specific antibody and T cell responses. These results suggest that 
asymptomatic MTB-infection could also interfere with prospective HIV vaccination in 





















MTB infection changes humoral and cellular immunogenicity of HIV 
DNA/protein vaccine.  
 
Characteristics of HIV specific immune response impairment in MTB infected 
animals are: 
 
• Lower titers of IgA in vaginal secretions and IgG in serum after intranasal 
vaccination 
• Lower neutralizing capability of serum after intramuscular vaccination 
• Lowered or reversed IgG1/IgG2a ratio regardless of vaccination route 
• Lower number of INFγ producing CD4+ and CD8+ cells regardless of 
vaccination route 
• Diminished triple and double cytokine producing CD4+ T-cell numbers after 




3.4 STUDY IV 
A murine model of Mycobacterium tuberculosis/HIV co-infection for studies on pathogen-
specific T cell responses in vivo 
Current models of HIV and TB infection in humanized mice does not allow for easy 
genetic manipulation of the host and are unpractical in long-term infectious studies 
[140], [146]. The non-human primate provides a successful model of MTB/HIV co-
infection, but it is a costly alternative, does not allow for easy genetic manipulation 
of the host and evokes additional ethical issues [397]. The growing need for a robust 
mouse model of MTB/HIV co-infection therefore becomes apparent. We decided to 
utilize the EcoNDK (MuLV/HIV-1 NDK isolate) chimeric virus developed by Potash 
et.al. and combined it with MTB aerosol infection of mice that are more or less 
susceptible to TB [48], [389].  
3.4.1 EcoNDK does not influence the lung bacterial burden and health 
of MTB/EcoNDK co-infected mice.  
To determine if Mtb/EcoNDK co-infection accelerates disease progression in MTB-
susceptible DBA/2 compared to resistant BALB/c mice, we infected groups of these 
animals with MTB (Harlingen strain) via the respiratory route. Three weeks later, 
groups of mice were co-infected with the EcoNDK virus intraperitoneally. To assess 
the impact of EcoNDK on disease progression, we monitored the weight of the 
animals and plated lung homogenates on Middlebrook 7H11 agar to determine the 
bacterial load. To date, we have not observed any significant differences in body 
weight and bacterial burden between MTB-infected mice and MTB/EcoNDK co-
infected animals. 
3.4.2 Reduced numbers of antigen-specific CD8+ T-cells in the lungs 
of susceptible DBA/2 mice during pulmonary TB. 
Because resistant BALB/c mice and susceptible DBA/2 mice express MHC class I of H-
2d, used the same MHC class I-multimer (H-2Kd) loaded with a MTB-derived peptide 
(TB10.420-28) to examine the antigen-specific CD8+ T-cell compartment in infected 
lung tissue in susceptible mice. After week three post infection, we observed that 
the number of antigen-specific CD8+ T-cells remained essentially unchanged in 
DBA/2 mice. In comparison, the number of antigen-specific CD8+ T-cells increased 
significantly after week 3 post infection in infected BALB/c lungs. This shows that 
recruitment of CD8+ T-cells is impaired in susceptible mice. We are currently 
conducting co-infection experiment with the use of these animals. Our MTB/EcoNDK 
co-infection model allowed us to extend these observations and to monitor how the 
TB10.4-specific CD8+ T-cell response was affected by EcoNDK co-infection. 
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3.4.3 Characterization of the MTB-specific CD8+ T-cell response 
during the early stage of MTB/EcoNDK co-infection. 
To investigate the possible impact that EcoNDK infection may have on the early 
MTB-specific response, we identified total CD4+- and CD8+ T-cells, as well as TB10.4-
specific CD8+ T-cells in the spleen and in the lungs. Two weeks after co-infection was 
established, the total number of CD4+ T cells and CD8+ T cells in the lungs and in the 
spleen was not significantly different in Mtb-infected mice compared to 
Mtb/EcoNDK co-infected animals. Analysis of the TB10.4-specific CD8+ T-cells in the 
spleen revealed that both the percentage and the absolute number of MTB-specific 
CD8+ T cells were significantly higher in MTB/EcoNDK co-infected mice. It is worth 
noting that the frequency of TB10.4-specific CD8+ T-cells in the spleen was 10-fold 
lower than in the infected lungs. Additionally, The number of TB10.4-specific CD8+ 
T-cell was not significantly different in the lungs. However, we did observe that lung 
antigen-specific CD8+ T-cells in co-infected animals expressed higher cell surface 
levels of the αβ T-cell receptor.  
We examined the cell surface expression profile of Tim3 and PD1 on TB10.4-specific 
CD8+ T-cells to to start addressing how MTB/EcoNDK co-infection influences 
regulation of the MTB-specific T-cell response. Our results revealed different usage 
of PD-1 and Tim3 on CD4+- and CD8+ T-cells in MTB-infected mice.  Up to 5% of the 
CD4+ T-cells in the MTB-infected lungs and in the spleen expressed Tim3. In 
comparison, over 15% of lung CD4+ T-cells and nearly 10% of splenic CD4+ T-cells 
expressed PD-1. We also noted that most Tim3+ CD4+ T-cells in the lungs co-
expressed PD-1.  
Because infection with EcoNDK led to an increased number of TB10.4-specific CD8+ 
T-cells, we investigated the PD-1 and Tim3 expression profile on MTB-specific CD8+ 
T-cells. Strikingly, TB10.4-specific CD8+ T-cells in the lungs were enriched for Tim3+ 
(∼40%) and PD-1+ cells (∼20%). Also, TB10.4-specific CD8+ T-cells that were Tim3+ 
to a large extent co-expressed PD-1. In comparison, even though Tim3 expression 
was elevated on MTB-specific splenic CD8+ T-cells, the overall frequency of Tim3 
expression in the spleen was lower than in the lungs. We did not detect any 
difference in Tim3 and PD-1 expression profile when we compared MTB-infected 
mice and in MTB/EcoNDK co-infected mice. 
We analyzed the cytokine profile of antigen-specific CD8+ T-cells by intracellular 
cytokine straining. Similar to the PD-1 and Tim3 cell surface expression profiles, we 
did not detect any significant differences in cytokine production by T-cells isolated 
from MTB-infected mice or MTB/EcoNDK co-infected mice. 
We used PMA and ionomycin to reveal the functional potential of both CD4+- and 
CD8+ T-cells. After polyclonal stimulation, around 20% of Tim3+CD4+ T-cells 
produced both TNF and IFNγ, and approximately 10% produced one of the 
cytokines. Among Tim3-CD4+ T-cells, the majority produced only TNF and only 10% 
of the cells were able to produce both TNF and IFNγ. Within the Tim3+CD8+ T-cell 
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subset, polyclonal stimulation resulted in ∼40% of the cells producing both TNF and 
IFNγ. Approximately 30% of the Tim3+CD8+ T-cells produced IFNγ only and 
essentially no Tim3+CD8+ T-cells were single-producers of TNF. 
Antigen-specific stimulation of CD8+ T-cells isolated from the lungs revealed that the 
Tim3+ subset was enriched for cells producing pro-inflammatory cytokines. It is 
noteworthy that ∼45% of the Tim3+CD8+ T-cells expressed both TNF and IFNγ, while 
only ∼10% of the Tim3-CD8+ T-cells expressed both cytokines. Irrespective of Tim3 
expression, TB10.4-peptide stimulated cells contained few single-producers.  
3.4.4 Increased viral load in peripheral tissues and secondary 
lymphoid organs of Mtb/EcoNDK co-infected mice. 
We isolated genomic DNA from the lungs and from the spleen, and performed 
quantitative PCR amplification of an EcoNDK-specific region of the gag gene to 
evaluate if MTB co-infection influenced the levels of the provirus in peripheral 
tissues and secondary lymphoid organs. Animals that were negative for the PCR 
product were excluded from the study.  
We observed productive viral infection in the spleen and in the lungs, with provirus 
levels averaging 600-650 infected cells/106 total cells in the spleen, and 150-250 
infected cells/106 total cells in the lungs. Interestingly, in co-infected animals the 
levels of proviral DNA was significantly higher in both organs comparing to animals 
that were infected with EcoHIV only. The total number of cells increases dramatically 
Figure 11.  EcoNDK virus burden 2 weeks after infection. Black filled markings present mice 
infected with MTB 3 weeks prior to virus infection. Empty markings represent 
virus-only infected animals.  
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in peripheral tissues and in secondary lymphoid organs during pulmonary TB. 
Therefore, the total number of provirus in co-infected animals is dramatically higher 
than after EcoNDK infection.  
These experiments clearly show that we were able to successfully infect 
immunocompetent wildtype with both EcoNDK and MTB, and thereby creating a 
unique small animal model of MTB/HIV co-infection. Additionally we showed that 
MTB infection significantly increased the viral burden during the early stage of co-
infection. We are currently utilizing the MTB-susceptible DBA/2 strain to further 
delineate how the chimeric virus influences the functional potential of MTB-specific 
CD8+ T-cell responses, and assessing the HIV-specific immune response. 
3.4.5 Discussion 
We have successfully established an MTB/HIV co-infection model in inbred, non-
modified mouse strains. Modeling HIV-1 infection in rodents presents numerous 
obstacles described in detail in the 1.2 section of the introduction. One approach to 
overcome the inability of HIV to infect murine cells is to modify the virus itself. 
Developed by Potash et al., the chimeric MuLV/HIV (EcoHIV and EcoNDK) viruses 
were shown to successfully infect conventional, immunocompetent WT mice. 
Recently is has been shown that this virus is establishing a chronic infection [154]. 
Although modification of the virus changes the binding receptor from CD4 to mCAT-
1, it productively infects activated murine splenocytes in vitro, including up to 10% 
of CD4+ T-cells [48], [398].  Similarly to the previous studies we have been able to 
infect mice after i.p. administration of the purified virus, reaching an infectivity rate 
of 80% [48], [154]. The levels of provirus detected in EcoNDK-infected animals were 
slightly lower comparing to other studies which could be a result of lower quality of 
the virus preparation, or slightly lower inoculum [152]. Importantly, we could detect 
the virus in animals co-infected with MTB and EcoNDK. The frequency of provirus in 
lung tissue and spleen was 1.5 to two times higher in co-infected animals compared 
to animals that were infected with EcoNDK only. Due to proliferation and 
recruitment of both myeloid and lymphoid cells into the lungs and spleen during 
MTB infection, the overall amount of provirus is several fold higher in co-infected 
animals. This finding is in agreement with clinical observations by Nakata et. al. on 
bronchoalveolar lavage (BAL) from MTB/HIV co-infected individuals. Lungs infected 
by MTB contained higher levels of HIV-1 branched DNA (bDNA) than samples 
collected from MTB-free samples. Interestingly, in these studies the viral load in the 
lungs was higher than in plasma of co-infected patients. Because the viral load in the 
lungs of the patients decreased after antibiotic treatment this suggest a close 
connection between viral load and bacterial burden [313]. Therefore, we are 
currently investigating how co-infection affects the viral burden in MTB susceptible 
DBA/2 mice, which harbor much higher amount of bacteria in the lungs [389]. On 
the other hand, in a recent macaque co-infection study, no increase in peripheral 
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virus replication was described during co-infection. A small number of animals could 
be responsible for lack of statistical significance in the obtained data [317].  
As expected, acute infection with EcoNDK did not change the CFU or health 
condition of MTB/EcoNDK co-infected mice. The results presented here were 
obtained from mice that were sacrificed only two weeks after virus infection. If the 
bacterial load is affected during later timepoints of co-infection needs to be 
determined.  
CD8+ T-cells are required for optimal host immunity and protection during 
pulmonary tuberculosis [399], [400]. We used MHC class I-multimer technology to 
monitor the MTB-specific CD8+ T-cell response in MTB/EcoNDK co-infected mice. 
After co-infection with EcoNDK we observed an increased frequency of TB10.4 
specific CD8+ T-cells in spleens, and a similar trend in the co-infected lung tissue. 
This also correlated with an increased absolute numbers of antigen-specifc CD8+ T-
cells. We showed that large fraction of these cells expressed Tim3 and PD-1, and 
about 20% of the cells co-expressed these two markers. In studies of chronic viral 
infections, and to some extend in clinical observations from TB patients, these 
proteins are considered to be markers of cell exhaustion [103], [105], [110], [111], 
[401], [402]. If PD-1 and Tim3 can be used as markers for antigen-specific T-cell 
exhaustion in our co-infection model needs to be determined. At the early stage of 
co-infection, we showed that Tim3 and PD-1 expression, as well as ability of these 
cells to produce cytokines, is similar for MTB and in MTB/EcoNDK co-infected 
animals. Still, co-infection induced a higher frequency of splenic TB10.4 antigen-
specific CD8+ T-cells. Therefore co-infection induced a higher number of antigen-
specific Tim3+ IFNγ- and TNFα-producing cells. Further investigations during later 
stages of co-infection are needed to determine if MTB- or EcoNDK-specific T-cells 
acquire an exhausted phenotype in our murine model. Also, we report increased 
viral replication in animals co-infected with MTB. How viral-specific host immunity is 
affected during MTB/EcoNDK co-infection also needs to be determined.   





Using chimeric MuLV/HIV virus and low-dose aerosol MTB infection we 
established new murine model of MTB and HIV co-infection in conventional 
BALB/c mice: 
In our preliminary data co-infected animals comparing to MTB only infected 
controls had: 
• Higher virus burden in lungs and spleens 
• Same bacterial burden and physical fitness 
• Significantly increased frequency of MTB specific CD8+ T-cells in spleens and 
elevated frequency of these cells in the lungs 
• Significant percentage of MTB specific CD8+ T-cells route expressing Tim3 
or/and PD1 in the lungs 
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